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Hematopoiesis and hematopoietic stem cells. Hematopoiesis is the process of blood cell 
development and formation. Blood contains many specialized mature cell types, such as red 
blood cells (erythrocytes), platelets (thrombocytes), granulocytes, macrophages, and B- and 
T-lymphocytes, that all play important roles in the function of an organism, ranging from oxygen 
supply to all tissues, to defense against pathogens. Since these cells have a limited lifespan, they 
have to be continuously replenished to sustain steady state levels in the peripheral circulation. 
Approximately 1011–1012 new blood cells are produced daily, by a small population of hematopoietic 
stem cells (HSCs).1-3 This multipotent cell population resides on the top of the hematopoietic 
hierarchy and through a cascade of differentiation steps HSCs can replenish all mature blood 
lineages. As a result of early commitment and proliferation, HSC give rise to multipotent 
progenitor cells (MPP), which become further restricted in their developmental potential and 
differentiate into progenitors of lymphoid or myeloid or mixed lympho-myeloid lineage (CLP, 
CMP or LMPP, respectively).4-7 Progenitors of myeloid lineage commit further into granulocyte/
macrophage progenitors (GMP) that arise from CMP or LMPP, or into megakaryocytic/erythroid 
progenitors (MEP) that originate from CMP. Eventually these distinct committed progenitors 
differentiate into all mature blood cells types, completing the hematopoietic differentiation 
cascade (Figure 1). For lifelong hematopoiesis the maintenance of the HSC pool is crucial and 
relies on long-term self-renewal potential, a unique feature of stem cells that is gradually lost 
as cell commit into one of the blood lineages. Thus, the ability of multilineage differentiation 
and self-renewal are the hallmark features of HSCs. The intricate balance between these two 
stem cell fates is essential to maintain homeostasis between the number of stem cells and their 
differentiated progeny, and is required to enable rapid and robust response to physiological 
stresses, including blood loss, infection and injury. Properties of HSCs render these cells an 
attractive source for a wide range of stem cell-based therapies where restoration of blood cells or 
introduction of normal hematopoiesis is needed, such as in malignancies, bone marrow failure, 
immunodeficiencies and genetic disorders. However, progress in the clinical applications of 
HSCs has been restricted by the limited stem cell numbers available for transplantations from 
some stem cell sources, such as umbilical cord blood. Therefore attempts have been made 
to amplify HSC numbers ex vivo, prior their transplantations. The success of ex vivo stem cell 
expansion protocols is dependent on our ability to manipulate the behavior of HSCs; to stimulate 
cell proliferation with concomitant maintenance of self-renewal potential. Development of such 
protocols requires methods for identification and characterization of HSC, understanding of the 
mechanisms governing HSC self-renewal and differentiation decisions, and ultimately defining 
key factors stimulating HSC self-renewal divisions.
Characterization of hematopoietic stem cells. Murine HSCs were identified for the first time by 
Till and McCulloch more than 50 years ago1,2 , and nowadays are the best characterized adult stem 
cells in terms of markers that allow their purification, but also in terms of assays for functional 
potential. Tools allowing HSC functional characterization, in combination with development 
of selection methods based on cell surface markers, advanced the prospective identification 
and isolation of stem cells. Changes in cell surface marker expression reflect HSC differentiation 
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and allow distinction of separate intermediate stages along the differentiation hierarchy. 
Studies have indicated that murine HSCs are contained within a cell population that lacks the 
expression of surface markers specific for mature blood cells (so-called lineage markers), but 
do express both Stem Cell Antigen-1 (Sca-1) and c-kit.8,9 Therefore, the HSC-containing subset 
of bone marrow is known as the LSK population. This compartment can be further subdivided 
in primitive, long-term (LT) HSC (representing only ~2% of LSK population), short-term (ST) 
HSC and multipotent progenitors (MPPs) based on the expression profile of additional markers, 
such as CD34, Flk-2/Flt-3, SLAM (CD48, CD150), and EPCR (CD201) (Figure 1).10-15 Alternatively, 
the HSC-enriched cell population can be identified based on the ability to efflux DNA-binding 
Figure 1. Model of hematopoiesis. On the top of hematopoietic differentiation hierarchy resides the 
multipotent stem cell compartment, consisting of long-term (LT-HSC) and short-term (ST-HSC) HSCs. 
Self-renewal capacity is restricted to this stem cell compartment and gradually decreases moving 
downwards the hierarchy (indicated by the triangle). Upon differentiation, HSCs give rise to all mature 
blood cells through a cascade of distinct and developmentally restricted progenitor stages, including 
multipotent progenitors (MPP), lymphoid primed multipotent progenitors (LMPP), common lymphoid 
progenitors (CLP), common myeloid progenitors (CMP), granulocyte/macrophage progenitors (GMP) and 
megakaryotic/erythroid progenitors (MEP).




































vital dyes such as Hoechst 33342 and the mitochondrial activity marker Rhodamine 123, marking 
the so-called side population (SP).16-18 However, the most important determinant in stem cell 
characterization is their functional potential. A number of assays have been developed to 
monitor hematopoietic stem and progenitor cell (HSPC) activity in vitro and in vivo. In vitro 
assays to measure HSPC potential include the colony forming unit assay (CFU), the cobblestone-
area forming cell assay (CAFC), and the long-term culture-initiating cell assay (LTC-IC).19,20 These 
assays allow for a relatively (compared to in vivo assays) quick estimate of the frequency and 
activity of stem and/or progenitor cells in a test cell population, and offer a method for screening 
the effects of a certain treatment (such as new compounds) on HSC function. Nonetheless, the 
ultimate proof of HSC function can only be obtained using the in vivo transplantation assay, 
measuring both self-renewal and multilineage differentiation capacity of test cells after transfer 
to a myeloablated host. Long-term reconstitution experiments following transplantation of a 
single purified cell provided functional proof of the existence of adult HSCs and showed their 
enormous proliferative and self-renewal potential.10 Experimental breakthroughs, including 
high-purity HSC isolation and separation of distinct differentiation stages, together with well 
established functional assays, greatly facilitated the study of key mechanisms and molecules 
involved in regulation of HSC self-renewal and differentiation.
Hematopoietic stem cell fate decisions and stem cell expansion. Quiescence, apoptosis, 
self-renewal and differentiation are all possible fates of HSCs. Elucidation of factors that 
control HSCs fate, specifically the ones promoting self-renewal and maintaining stem cells in 
an undifferentiated state, has been a long-standing goal of stem cell biology, as these factors 
potentially represent a means for promoting expansion of HSCs ex vivo. Self-renewal can be 
defined as a cell division in which one (maintenance) or both (expansion) of the daughter cells 
remain undifferentiated and retain the same properties as a parent cell. It is believed that in 
order for a stem cell to self-renew it must integrate survival signals, proliferation control and 
it has to repress alternative transcriptional fates, such as commitment into a certain lineage. 
In vivo, HSCs are exposed to a complex interplay of diverse signals, both cell autonomous 
(intrinsic) but also cell non-autonomous (extrinsic), ultimately determining the fate of dividing 
HSC. Gene manipulation and genome-wide expression profiling studies have proven to be 
important tools in delineating the mechanism playing a role in the regulation of HSC fate 
decisions. Several distinct cell intrinsic factors, such as chromatin remodelers21,22, transcription 
factors23-26, microRNAs27-31, signal transducers32, and anti-apoptotic signals33,34, but also signals 
from the rich milieu of the cell, molecules produced by HSC microenvironment (so-called 
niche), including growth factors35-40 and signals involved in HSC ontogeny41-48, have been shown 
to be able to affect HSC fates. However at present, a holistic perspective of how stem cells 
balance self-renewal versus differentiation decisions is lacking, and the regulatory networks 
orchestrating HSC self-renewal decisions remain to be determined. A remaining challenge 
is insight into if and how cell intrinsic and extrinsic signals are integrated with each other. 
Extrinsic control of HSC self-renewal and differentiation might be the preferred approach in 
clinical ex vivo HSC expansion protocols, since genetic manipulation of the cell might result in 
undesired clinical outcomes, for instance development of leukemia. However, in most cases 
extrinsic manipulation of self-renewal has proven to be difficult, since HSCs proliferation in vitro 
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inevitably leads to hematopoietic differentiation or death, with an overall loss of transplantable 
HSC activity. Therefore, many studies focus on the search for extrinsic molecules stimulating 
HSC self-renewal programs. More recently, the activity of non-hematopoietic factors, such as 
neuronal factors49 or chemical compounds50-53 was assessed, which opened new possibilities 
for ex vivo HSC expansion protocols. Nonetheless, the quest for (combinations of) factors 
that efficiently induce extensive HSC proliferation while simultaneously stimulating HSC self-
renewal and/or inhibiting HSCs differentiation in culture is still continuing. 
OUTLINE OF THE THESIS
In this thesis we aimed to explore the potential of distinct intrinsic and extrinsic factors to regulate 
HSC self-renewal and differentiation with the ultimate purpose of ex vivo stem cell expansion. 
Chapter 2 provides an introduction to the ex vivo stem cell expansion concept. It contains 
an overview of the known factors controlling HSC self-renewal, with the emphasis on extrinsic 
control of HSPC fate. Previous expansion approaches and more recent directions in HSPC 
expansion attempts are reviewed in this chapter. 
Chapter 3 describes a study aimed to identify new intrinsic regulators of hematopoiesis. In 
this chapter we profiled microRNA expression patterns during hematopoietic differentiation 
in two distinct mouse strains (C57BL/6 and DBA/2), and we identified microRNAs specific for 
HSPCs and correlating with HSPC frequency. Of special interest was an evolutionary conserved 
microRNA cluster 99b/let-7e/125a. To study whether members of this cluster could control 
HSPC fate decisions, the miRNAs were overexpressed in HSPCs, and we show that this led to 
initial expansion of primitive cells, but in the long-term resulted in stem cell exhaustion. Finally, 
using a bioinformatics approach, we identified candidate downstream targets through which 
miR-125a may be able to modulate HSPC fate. 
Chapter 4 illustrates the potential of small molecule compounds to manipulate HSPC fate 
decisions in culture. In this study, the combined effects of valproic acid (VPA) and lithium (Li) 
on HSPC proliferation, differentiation and self-renewal under strong differentiation pressure 
were investigated. We showed that the combination of these two compounds displayed strong 
anti-differentiation effects at the level of uncommitted and committed progenitors, both at 
the biological and molecular level. The combination of VPA and Li synergistically preserved 
expression of stem cell-related genes and repressed genes involved in differentiation.
 In Chapter 5 we studied the molecular mechanism underlying the enhancing effects of 
VPA on HSPC by profiling early response VPA mRNA targets. We identified Sca-1 as a direct 
VPA targets and showed that Sca-1 can be readily, quickly and efficiently re-induced on distinct 
hematopoietic cells subsets by VPA. Finally, we demonstrated that re-activation of Sca-1 
expression on hematopoietic cells correlated with enhanced self-renewal capacity. Although, 
Sca-1 was not necessary for the biologic effects of VPA, as shown when Sca-1 deficient cells were 
used, it marked HDI-responsive cells with enhanced functionality.
Chapter 6 summarizes the findings described in the previous chapters, and discusses a 
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CHALLENGES AND OPPORTUNITIES
Marta A. Walasek, Ronald van Os and Gerald de Haan
Modified from: 
Ann N Y Acad Sci. 2012 Aug;1266(1):138-50
CHAPTER 2
ABSTRACT
Attempts to improve hematopoietic reconstitution and engraftment potential of ex 
vivo-expanded hematopoietic stem and progenitor cells (HSPCs) have been largely 
unsuccessful due to the inability to generate sufficient stem cell numbers and to excessive 
differentiation of the starting cell population. Although hematopoietic stem cells (HSCs) 
will rapidly expand after in vivo transplantation, experience from in vitro studies indicates 
that control of HSPC self-renewal and differentiation in culture remains difficult. Protocols 
that are based on hematopoietic cytokines have failed to support reliable amplification of 
immature stem cells in culture, suggesting that additional factors are required. In recent 
years, several novel factors, including developmental factors and chemical compounds, 
have been reported to affect HSC self-renewal and improve ex vivo stem cell expansion 
protocols. Here, we highlight early expansion attempts and review recent development in 





The two defining features of hematopoietic stem cells (HSCs), self-renewal and multilineage 
differentiation, render these cells an attractive source for stem cell-based therapies. HSC 
transplantation can be a life-saving procedure in the treatment of a broad spectrum of disorders, 
including hematologic, immune, and genetic diseases. Bone marrow (BM) and mobilized 
peripheral blood stem cells are the most common HSC sources for transplantation; however, 
their use is restricted by the low availability of suitable human leukocyte antigen (HLA)-matched 
donors. An alternative approach, allowing the use of more rapidly available partly mismatched 
donors, involves the use of umbilical cord blood (UCB), which has been shown to be a rich 
source of HSCs. However, the stem cell number in a single UCB unit is not sufficient for 
transplantation into an adult.1 These two issues, the lack of HLA-matched donors and the low 
number of stem cells available from common HSC sources for transplantation, especially in the 
case of UCB, present serious limitations to HSC transplantations. Clinical experience has shown 
that the stem cell dose (measured as CD34+ cell number) is related to patient survival and time 
required for engraftment,1-3 indicating that amplification of hematopoietic stem and progenitor 
cells (HSPCs) is expected to be highly beneficial for their clinical applications. 
HSCs are a rare population of cells, representing less than 0.01% of all cells in the BM. 
During homeostasis, the stem cell pool is maintained at a relatively constant level. In contrast, 
several studies have shown that during hematopoietic stress, such as serial transplantations, 
HSCs can and will self-renew extensively. Studies by Pawliuk et al., Iscove, and Nawa have 
shown that following injection into lethally irradiated recipients, HSC numbers increased by 
10- to 20-fold.4,5 When these cells were serially transplanted, the initial number of transplanted 
HSCs increased cumulatively by 8,400-fold after four successive passages.5 Furthermore, it has 
been shown that a single purified HSC can reconstitute long-term hematopoiesis of lethally 
irradiated recipients, indicating robust in vivo self-replication capacity.6 These studies have 
unequivocally demonstrated that HSCs can massively expand, and suggest that in vivo stem 
cells are exposed to specific factors/signals that promote their self-renewal and amplification.
Although HSC self-renewal divisions in vivo clearly occur, induction of self-renewal in vitro 
has been difficult. Even after several decades of research, the quest for factors that stimulate 
self-renewal in vitro is still continuing. The aim of these studies is to define the culture conditions 
that will support unlimited ex vivo expansion of HSCs from any source. To achieve this goal, 
stimulation of symmetrical self-renewal divisions over differentiation divisions is required 
(Figure 1). Although many efforts have been made to expand stem cells, extensive in vitro 
amplification of HSCs without loss of their repopulating potential has not yet been achieved. 
Nonetheless, several cell-intrinsic and cell-extrinsic factors have been identified and shown 
to have potential to expand HSCs in culture. Here, we summarize how ex vivo HSC expansion 
protocols have evolved, briefly reviewing the early expansion attempts and then focusing on 
recent expansion approaches involving small molecules.





















Figure 1. HSC fate outcomes define the composition of ex vivo-expanded product. (A) Symmetrical 
HSC self-renewal division. As a result of this division the parent stem cell give rise to two daughter cells with 
the identical properties as the parent cell, increasing the stem cell pool. Occurring during development 
of hematopoietic system in fetal liver and upon BM transplantation, remains difficult to sustain during 
ex vivo stem cell culture. (B) Asymmetrical HSC self-renewal division. Following asymmetrical self-renewal 
the parent stem cell generates one identical daughter cells and a progeny committed to differentiation, 
thus preserving stem cell numbers. Occurring during hematopoietic homeostasis in adulthood and during 
ex vivo HSC expansion culture supporting stem cell maintenance. (C) Symmetrical HSC division. Outcome 
of symmetrical cell division is generation of two committed to differentiation daughter cells, leading to 
stem cell depletion. Occurring in a pathological conditions characterized by stem cell exhaustion and 
usually during ex vivo HSC culture. (D) HSC expansion today and the ‘Holy Grail’ of expansion research. 
Ex vivo HSC expansion protocols available today cannot efficiently support symmetrical self-renewal 
divisions of HSC resulting (optimistically) in maintenance or minor amplification of stem cells and 
expansion of differentiated progeny. It remains unclear whether stem cells from any source benefit from 
up-to-date expansion protocols, resulting in lack of standardized on-demand expanded product. The 
challenge remains to expand undifferentiated HSC (via stimulation of symmetrical self-renewal divisions) 
in numbers sufficient for therapy of adult patients. This would allow development of clinically relevant and 
quality-controlled HSPC expanded product that can be supplied upon demand.
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REGULATION OF HSC SELF-RENEWAL By INTRINSIC FACTORS
One of the remaining fundamental questions of stem cell biology is how self-renewal is 
regulated. Answers to this question would also substantially contribute to the success of ex vivo 
HSC expansion protocols. Valuable knowledge about factors influencing self-renewal has been 
gained from gene manipulation studies, which have identified multiple proteins that play an 
important role in the regulation of HSC self-renewal, including transcription factors, epigenetic 
modifiers, and cell cycle regulators (Figure 2) (reviewed in Refs. 7 and 8). Here, we will only 
highlight a few examples, representing different classes of proteins, such as DNA-binding, 
chromatin-binding, and RNA-binding factors.
One of the first genes described to play a role in HSC fate determination was HoxB4. Ectopic 
expression of this transcription factor resulted in robust (40-fold) expansion of transplantable 
murine HSCs, but did not coincide with the development of leukemia.9,10 HSC amplification 
could also be stimulated by an extrinsically delivered TAT-HoxB4 fusion protein, although 
the HSC expansion levels achieved with this fusion protein were much lower compared with 
ectopic protein expression.11 Additionally, other members of HoxA and HoxB clusters (e.g., 
HoxA4, HoxA9, HoxB6) have also been shown to regulate fate determination of adult HSCs.12-15 
Overexpression of chromatin remodelers, such as members of the Polycomb group family of 
proteins (PcG), especially Ezh2 or Bmi1, have been shown to modulate HSC activity by preventing 
stem cell exhaustion or augmenting self-renewal, respectively.16-18 The recent discovery of 
noncoding RNAs, including microRNAs, added an additional level of regulation to the network 
controlling HSC fate determination.19,20 MicroRNAs are short RNA molecules, 19-25 nucleotides 
in length that negatively regulate gene expression. Sequence-specific pairing of microRNA with 
targeted messenger RNA results in inhibition of its translation and/or triggers messenger RNA 
degradation.19 MicroRNAs are predicted to modulate the expression of hundreds of messenger 
RNAs, profoundly affecting cellular gene expression profiles.20;21 Thus, microRNAs might act 
as master regulators of cellular transcriptional programs. A growing body of studies indicates 
that microRNAs are critical players orchestrating developmental or differentiation stages of 
many distinct tissues, including hematopoiesis.19;22;23 Ablation of Dicer, the enzyme required for 
microRNA processing resulted in an impairment of the HSC compartment in mice, indicating 
an essential role of microRNAs in HSCs maintenance.24,25 Several microRNAs enriched in the 
stem cell compartment compared to bone-marrow cells, such as the miR-125 family and 
miR-29a, have been reported to affect HSPC self-renewal and differentiation decisions.26-28 
However, ectopic expressions of these microRNAs can lead to the development of leukemia 
or myelodysplastic syndrome.24;26-30 Genetic studies aimed to decipher the mechanism of self-
renewal have indicated that self-renewal is regulated at various levels and likely by a complex 
network of interacting stimuli.
Although the highest expansion levels have been reported after ectopic expression of 
cell-intrinsic genes, introduction of genetic material is undesired in clinical protocols since 
continuous activation of self-renewal may lead to potential malignant transformation or to 
stem cell exhaustion. Therefore, mild and/or transient activation of self-renewal by extrinsic 
factors or molecules that perturb the activity of intrinsic HSC self-renewal regulators (described 
above) might be a preferred tool for ex vivo stem cell expansion. 
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EXTRINSIC REGULATORS OF HSC FATES
The first attempts to ex vivo amplify HSCs with extrinsic factors focused on the use of 
hematopoietic cytokines, many of which are produced by the in vivo HSC microenvironment. 
Although the role of cytokines in blood lineage development has been indisputably established, 
their regulatory role on HSC self-renewal has been questioned.31-33 Multiple cytokines, including 
SCF, Tpo, Flt-3L, IL-11, IL-3, IL-6 and GM-CSF, and combinations of these, have been studied in in 
vitro HSC expansion protocols of mouse and human cells. For details of the effects of distinct 
cytokines on HSC characteristics in culture, we refer to the excellent review by Sauvageau 
et al.33 Knowledge gained from cytokine studies indicates that whereas in vitro cell survival and 
proliferation can be efficiently stimulated by several cytokines (especially SCF and Tpo), these 
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Figure 2. Cell-intrinsic and cell-extrinsic factors involved in HSC self-renewal. Self-renewal can 
be driven intrinsically by gene expression and can be regulated by extrinsic factors from environment. 
Cell-intrinsic regulation of HSC fate includes interplay between specific transcription factors, RNA/DNA-
binding proteins and chromatin-associated factors. That network can be modulated by cell-extrinsic cues, 
like cytokines, developmental/growth factors and chemical compounds. These distinct stimuli create 
complex matrix of interactions that define the result of HSC fate suggesting that combination of distinct 




cytokines by themselves are usually not sufficient to support self-renewal and they typically 
induce HSC differentiation, resulting at best in maintenance or modest stem cell amplification, 
but usually leading to progressive depletion of long-term repopulating cells.34,35 Single cell 
cytokine cultures demonstrated that in vivo repopulating ability of mouse and human HSCs is 
gradually but inevitably lost, starting from the first in vitro cell division.36-38 Nonetheless, the 
cocktails of SCF and Flt3L with IL-11 (mouse) or Tpo (mouse and human) was defined as the 
cytokine combination supporting the best HSPC survival, proliferation, and maintenance during 
in vitro culture, and is often used as the core cytokine mix to which other cytokines or expansion 
factors can be added (Table 1).39-41 To conclude, efforts to improve the rate of HSPC engraftment 
by ex vivo cytokine-based expansion protocols has been largely unsuccessful, indicating the need 
of additional factors/molecules in order to support HSC self-renewal and amplification in vitro.
DEVELOPMENTAL REGULATORS AND HSC EXPANSION
Recently, factors that do not necessarily qualify as typical hematopoietic growth factors but 
rather play an instructive role during ontogeny (i.e., at a time when the hematopoietic system 
is first developed and is rapidly expanding) have been shown to also regulate the adult stem 
cell compartment. These factors stimulate several developmentally conserved pathways, 
such as wingless-type (Wnt), Notch, Sonic hedgehog (Shh), and fibroblast growth factor 
(FGF) signaling. Adult HSCs have been shown to express receptors that can activate all of the 
aforementioned pathways, indicating that these pathways may be employed to extrinsically 
control HSC fate in culture.
Wnt proteins. The Wnt signaling pathway, known by its role in embryogenesis and cancer, 
regulates cell-to-cell interactions in a wide variety of tissues. A role for Wnt has been convincingly 
demonstrated in homeostasis of the intestinal stem cell compartment,42 and a role for Wnt has 
been explored in HSC fate regulation.43 Wnts are secreted glycoproteins, expressed by the fetal 
and adult HSC microenvironment. Addition of soluble Wnt proteins, such as Wnt3a or Wnt5a, to 
liquid cultures or co-cultures with Wnt-transduced stroma, enhanced mouse and human HSC 
survival, proliferation, and self-renewal, as measured by engraftment rate after transplantation 
into lethally irradiated recipients.44-47 Interestingly, it has recently been demonstrated that the 
level of Wnt signaling is critically important in regulating HSC self-renewal.48 Binding of Wnt 
ligands to its receptor Frizzled triggers activation of the canonical signal transducer β-catenin 
and its translocation to the nucleus, leading to activation of Wnt target gene transcription.49 
Ectopic expression of a constitutively active form of β-catenin resulted in expansion of the 
stem cell pool.43 In this study, upon activation of Wnt signaling, upregulation of HoxB4 and 
Notch1 were reported, suggesting a link between Wnt and Notch signaling pathways. Work 
of Duncan et al. supports cooperation of these two pathways in maintaining the HSC pool, 
thus demonstrating the importance of the Wnt pathway in cell proliferation and survival and a 
requirement of Notch for maintaining HSCs in an undifferentiated state.50
Notch pathway. Notch and Notch-ligands, such as Jagged-1, Jagged-2, and Delta-1, are 
expressed by HSCs and their microenvironment, indicating a potential role for Notch 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































interactions in hematopoiesis.51 Studies on the involvement of the Notch pathway in HSC 
fate regulation demonstrated that an immobilized form of Delta-1, but not its soluble form, 
can expand murine and human HSPCs in culture. Incubation of human UCB CD34+ cells with 
Delta-1 and cytokines resulted in increased numbers of NOD/SCID repopulating cells with 
secondary transplantation ability. Similar to the dependence of HSCs on Wnt-protein levels, 
the Notch-mediated effects were suggested to be dose-dependent, since HSPC expansion was 
observed only with lower Delta-1 concentrations.52,53 A subsequent clinical phase I trial showed 
rapid neutrophil recovery, enhanced myeloid engraftment, and no signs of graft-versus-host 
disease (GVHD) following transplantation with Delta-1-expanded human UCB cells,54 although 
it remains unclear whether the UCB cells benefitted from the expansion protocol.
Shh / BMP signals. Cytokine-based expansion cultures of HSCs can also be improved by 
addition of other developmental factors, namely by soluble Sonic hedgehog proteins (Shh). 
Following Shh stimulation of human CD34+CD38-Lin- cells, enhanced cell proliferation and 
increased recovery of NOD/SCID repopulating cells were reported.55 Additionally, Shh-induced 
HSPC expansion was suggested to be dependent on downstream bone morphogenic protein-4 
(BMP-4) signaling, because inhibition of BMP-4 abrogated Shh-induced expansion.55 Since 
human HSCs express BMP receptors, addition of soluble BMP-4 could also improve human 
HSPC proliferation and maintenance following in vitro culture.56
FGF signaling. The observation that murine HSCs express high levels of FGF receptors has led 
to investigation of the role of FGF signaling in HSPC fate regulation. Among this large protein 
family, FGF-1 and FGF-2 in particular were shown to maintain/expand multilineage, serially-
transplantable, long-term repopulating HSCs when added to cytokine- and serum-free cultures 
of unfractionated mouse BM.57,58 However, addition of classical cytokines to these cultures and 
stimulation of proliferation overruled FGF-dependent stem cell preservation. Moreover, FGFs 
could not support the maintenance of an undifferentiated state of purified murine HSC in 
culture, and only appeared active when stromal elements were present, suggesting an indirect 
nature of the FGF effects.58
IGF and Angptls. Recently, several soluble proteins produced by the endothelium and fetal liver, 
including insulin-like growth factor 2 (IGF-2), IGF binding protein 2 (IGFBP-2), and angiopoietin-
like proteins (Angptls), have been identified as growth factors that can enhance ex vivo 
expansion of HSCs. Zhang et al. reported that addition of IGF-2, a protein expressed in fetal liver 
cells, to serum-free cultures of fetal liver HSCs resulted in increased stem cell frequency in a 
transplantation setting.59 Shortly afterward, it was reported that IGFBP-2 displayed similar or even 
better stem cell-supporting effects and that IGF-2 could be replaced by IGFBP-2 in ex vivo HSC 
expansion cultures.60 These cultures also contained a combination of a developmental factor, 
FGF-1 (mentioned above), and two cytokines, SCF and Tpo. The efficiency of this expansion 
cocktail could be further enhanced by addition of angiopoietin-like proteins,61 which include 
several members, such as Angplt2, Angplt3, Angplt5, and Angplt7. Culture of murine HSCs with 
these factors resulted in a 30-fold net expansion of long-term repopulating HSCs, one of the 
highest HSC amplifications achieved to date by extrinsic factors. Similar expansion levels have 
also been reported in human HSC cultures supplemented with the Lodish and Zhang cocktail.60-62
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Pleiotrophin. Another novel microenvironmental factor, pleiotrophin, expressed by human 
brain endothelial cells, has recently been reported to be essential for HSC maintenance. Mouse 
HSCs cultured in the presence of Pleiotrophin displayed a net increase in in vivo-measured 
stem cell frequency and enhanced secondary repopulation activity upon serial transplantation. 
Pleiotrophin was also shown to improve ex vivo expansion of human CD34+CD38-Lin- HSCs, 
albeit to a lesser extent compared with murine cells. Pleiotrophin-mediated expansion was 
abrogated by addition of specific PI3K or Notch inhibitors to the culture medium, suggesting 
involvement of these pathways in the pleiotrophin stem cell-enhancing effects.63 Additionally, 
whereas pleiotrophin deficiency did not show any in vivo steady-state hematopoietic effects, 
repression of pleiotrophin in stromal cells resulted in defective hematopoiesis.64
The studies discussed above indicate the potential usefulness of exploiting the molecular 
pathways involved in stem cell self-renewal in improving ex vivo HSPC amplification cultures. 
The challenge remains to integrate the various cell-intrinsic and cell-extrinsic signals into the 
regulatory networks controlling HSC fate outcomes and to decipher how these factors are 
linked with each other. Likely, the balance of various co-regulated stimuli, acting simultaneously 
or sequentially, is crucial for HSC fate outcomes, and the ability to mimic the orchestra of these 
signals may lie in the success of in vitro stem cell-expansion protocols.
SMALL MOLECULES
In recent years, evidence has accumulated suggesting that in addition to natural cytokines/
factors chemical compounds can also have potent effects on stem cell expansion protocols 
(Table 1). Studies were launched to assess the ability of such compounds to control stem cell fates 
in culture, where the effects ranged from enhancement of stem cell expansion to stimulation of 
lineage-specific differentiation, including effects on iPS reprogramming efficiency.65-67
ATRA. Retinoic acid (RA), a derivative of vitamin A (retinol) normally present at low physiological 
concentration in serum, represents a naturally occurring small molecule.68 Retinoids have 
been shown to play important roles in development, differentiation and homeostasis of a 
wide variety of cell types. The retinoic acid receptor agonist all-trans retinoic acid (ATRA) has 
a well-documented effect on hematopoietic cells in cancer treatment, where it can induce 
differentiation of leukemic cells.69 Studies with RA receptor (RAR) deletion have revealed 
the importance of retinoids in normal hematopoiesis, since RAR-γ knock-out mice showed 
markedly reduced HSC numbers.70 However, the utility of retinoids for ex vivo HSPC expansion 
is unclear. Purton et al. suggested that addition of ATRA to cultures of mouse HSPCs enhanced 
the maintenance of short- and long-term repopulating cells and augmented self-renewal in 
serial transplantation experiments.71,72 Additionally, increased Notch1 and HoxB4 mRNA levels 
were observed upon ATRA stimulation, suggesting that ATRA effects could be at least partially 
mediated via known cell-intrinsic regulators of HSC self-renewal.70 On the other hand, retinoic 
acid was also reported to negatively affect HSPC ex vivo expansion, since inhibition of retinoid 
signaling resulted in enhanced HSPC self-renewal in vitro.73 Therefore, the effects of retinoids 




Copper chelator, TEPA. It has been shown that increased cellular copper levels can improve 
ATRA-stimulated differentiation of leukemic cells.74 Additionally, ions such as magnesium, 
calcium, or copper (Cu) are known to play an important role in cell function, since disturbed 
homeostasis of these ions is associated with clinical symptoms. Copper malnutrition resulted 
in hematopoietic cell maturation arrest but did not affect progenitor cell development, which 
suggests that cellular Cu balance may play a role in HSPC proliferation and differentiation. 
Studies on modulation of cellular Cu content during ex vivo culture demonstrated that 
elevated copper levels accelerated cell maturation, whereas decreased Cu levels, achieved 
by addition of the Cu chelator tetraethylenepentamine (TEPA), attenuated ex vivo human 
HSPC differentiation, resulting in expansion of early progenitor cells. TEPA-supplemented, 
long-term cytokine cultures of CD34+ cord blood cells significantly increased the number of 
CD34+CD38– cells and enhanced NOD/SCID repopulating capacity.74,75 A phase I/II clinical trial in 
which TEPA-cultured cord blood cells were coinfused with uncultured cord blood cells showed 
the safety of this approach.76 Although engraftment of TEPA-treated cells could be observed 
in almost all study subjects, the time required for neutrophil and platelet recovery was not 
changed compared with uncultured cord blood cells.76 The efficiency of TEPA-cultured HSPC 
transplantation product is currently under investigation in an ongoing phase II/III study.
HDIs. Since stem cells are believed to be characterized by a specific (transcriptionally permissive) 
epigenetic status, epigenetically active compounds could possibly modulate stem cell fates. 
Several small molecules have been identified that alter the epigenetic status of cells. Histone 
deacetylase inhibitors (HDIs) or demethylating agents are example of such compounds. 
Several groups have studied the effects of valproic acid (VPA), an epigenetic drug known for 
its anticancer activity, on the regulation of in vitro HSC fate determination. Addition of VPA to 
cultures of murine or human HSPCs preserved the expression of primitive markers and an HSC 
phenotype.77-79 VPA treatment was shown to maintain CFU-S activity in murine HSCs and resulted 
in elevated chimerism levels upon transplantation into lethally irradiated recipients.77-80 Similar 
effects on the ex vivo expansion of human-mobilized peripheral blood CD34+ HSCs were observed 
upon treatment with another HDI, chlamydocin.81 Additionally, a combination of two epigenetic 
drugs was shown to additively affect HSC maintenance and/or expansion in culture.82,83 Sequential 
addition of a demethylating agent, 5-aza- 2’-deoxycytidine methyltransferase (5azaD), and the 
HDI trichostatin A (TSA) to various cytokine cocktails has been shown to improve maintenance 
of stem cells in culture, compared with single compound treatment.82,83 As expected, in these 
HSCs, HDI exposure increased histone acetylation, whereas 5aza decreased methylation.82 HDI 
treatment has also been shown to result in up-regulation of cell-intrinsic HSPC fate regulators such 
as HoxB4 and AC133, in activation of Wnt signaling, and in down-regulation of p21. Nevertheless, 
the exact mechanism of HDI-stimulated HSC expansion remains unclear.77-83
BIO. Small molecules that specifically target signaling pathways that play an important role in 
HSC self-renewal and maintenance could be beneficial for ex vivo expansion protocols. The 
synthetic compound 6-bromoindirubin-3’-oxime (BIO) can modulate Wnt signaling activity by 
targeting GSK3α and β, a negative regulator of Wnt signals. Stimulation of cord blood CD34+ 
cells with BIO led to accumulation of slowly dividing cells and enhanced replating activity.84,85 
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Additionally, the exposure of cultured CD34+ cells to BIO significantly increased engraftment 
and chimerism levels of the NOD/SCID repopulating cells.49 As a GSK3β inhibitor, BIO treatment 
resulted in accumulation of β-catenin and its nuclear localization; however, the expression of 
Wnt target genes was not changed upon treatment.84,85 Therefore, the key mechanism of BIO, 
and how it is responsible for enhanced HSPC activity, remain unknown.
SR1. Recent reports have shown that unbiased screens to search for factors that are able to 
maintain/expand HSCs can identify novel compounds with HSC self-renewal stimulatory 
activity. Using high-throughput screening, Boitano et al. identified an acryl hydrocarbon 
receptor (AhR) antagonist, referred to as StemRegenin1 (SR1) that was capable of enhancing 
human CD34+ HSC cell amplification.86 Cord blood CD34+ cells cultured in the presence of 
SR1 led to a high net increase in the number of CD34+ cells. Importantly, SR1-treated human 
cells demonstrated a 17-fold increase in cell numbers that were capable of hematopoietic 
reconstitution of sublethally irradiated mice and showed enhanced multilineage, long-term 
potential. Although it has been shown that hHSCs express AhR, which has been implicated 
in pathways regulating hematopoiesis, pathways including HES-1, β-catenin, and CXCR4, the 
exact mechanism of SR1-induced HSC expansion is not known yet.86
PGE
2. 





identified as a regulator of HSC self-renewal using high-throughput library screens in 
zebrafish.87 Chemicals enhancing PGE
2
 synthesis have been shown to increase HSC numbers 
in zebrafish and mouse embryos, whereas those blocking its synthesis decrease stem cell 
numbers, indicating that modulation of the prostaglandin pathway might affect stem cell 
characteristics.87 Components of the prostaglandin pathway and PGE
2
 receptors are present on 
both mouse and human stromal cells and HSCs.87,88 The enhancing role of PGE
2
 on adult HSCs 
has been demonstrated in competitive transplantation models, where short stimulation of 
mouse cells with PGE
2
 prior to transplantation increased the frequency of short- and long-term 
repopulating cells.87 Hoggatt et al. confirmed the stimulatory effects of PGE
2
 on mouse HSCs 
and additionally reported that the induced competitive advantage of treated HSCs remained 
upon serial transplantation. Although the exact mechanism of PGE
2
 is not known, studies have 
shown that the PGE
2
 effects might be explained by stimulation of HSC survival, proliferation, 
and self-renewal associated with upregulation of survivin, an inhibitor of apoptosis, and with a 
reduction of the active intercellular form of caspase-3. Furthermore, PGE
2
 may enhance HSPC 
homing, as suggested by upregulated expression of the CXCR4 gene.88
NR-101. The studies reported above have employed the use of chemical compounds added 
to cultures that also contain cytokines. Yet, small molecules have also been used as a 
full replacement of cytokines. Tpo is one of the most efficient cytokines supporting HSC 
proliferation and survival in culture and is widely used in HSC expansion protocols. Several 
small molecules have been chemically synthesized that are able to activate c-MPL, the receptor 
forTpo. Nishino et al. screened more than 400 of these molecules for their HSC stimulatory role 
and found a novel small molecule c-MPL agonist, NR-101 that more effectively expanded HSCs 
ex vivo compared with Tpo. Following culture, NR-101 increased CD34+ and CD34+CD38– cell 




blood CD34+ cells. NR-101 was shown to activate the major pathways of Tpo/c-MPL signaling, 
but displayed extended signal activation compared to Tpo.89 
Finding that HSPC fate can be modulated chemically by addition of small molecules to the 
culture media is convenient in light of ex vivo HSC expansion and offers, next to cytokines and 
developmental factors, an additional level of control of HSC self-renewal and differentiation in 
vitro. The promising potential of chemically enhanced HSC self-renewal and its cooperation 
with other self-renewal factors should be carefully evaluated and tested for use in clinical stem 
cell expansion protocols.
CONCLUSIONS
Although HSCs can expand extensively in vivo, conditions that reliably induce robust HSC 
expansion in vitro have yet to be discovered. Expansion attempts with the use of hematopoietic 
cytokines were rather disappointing and therefore diminished the initial enthusiasm of ex vivo 
stem cell expansion. A potential role of developmental factors and the discovery that self-
renewal can be controlled by chemical compounds has revived this hope. Today, thousands 
of molecules are screened for their effects on HSC fates, and the utility of these factors for 
in vitro stem cell expansion is being investigated. Experience gained from many years of research 
indicates that the most comprehensive approach to develop optimal HSC expansion conditions 
may involve a combination of methods. It is likely that these conditions would involve multiple 
biological and chemical compounds that act in concert to induce cell survival and division while 
simultaneously preventing stem cell differentiation. Accordingly, several signaling pathways 
and/or compounds have been reported to act additively or synergistically to modulate HSPC 
fates in culture.79,90,91 Additionally, methods that improve HSC homing and survival after 
transplantation could also be combined with ex vivo HSC expansion to potentially further 
enhance the efficiency of HSPC engraftment. Difficulties in defining HSC expansion conditions 
result partly from insufficient understanding of the molecular mechanisms controlling HSC fate 
determination. Identification of key molecules and the interaction networks important for self-
renewal could significantly improve expansion attempts and may also lead to development of 
specific compounds targeting these self-renewal factors. Importantly, the challenge remains to 
assess to what extent it will be possible to generate fully functional HSCs, and their derivatives, 
for future clinical regenerative medicine applications.
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CHAPTER 3
ABSTRACT
Hematopoietic stem/progenitor cell (HSPC) traits differ between genetically distinct mouse 
strains. For example, DBA/2 mice have a higher HSPC frequency compared with C57BL/6 
mice. We performed a genetic screen for microRNAs that are differentially expressed 
between LSK, LS-K+, erythroid and myeloid cells isolated from C57BL/6 and DBA/2 mice. 
This analysis identified 131 microRNAs that were differentially expressed between cell types 
and 15 that were differentially expressed between mouse strains. Of special interest was 
an evolutionary conserved miR cluster located on chromosome 17 consisting of miR-99b, 
let-7e, and miR-125a. All cluster members were most highly expressed in LSKs and down-
regulated upon differentiation. In addition, these microRNAs were higher expressed in 
DBA/2 cells compared with C57BL/6 cells, and thus correlated with HSPC frequency. To 
functionally characterize these microRNAs, we overexpressed the entire miR-cluster 
99b/ let-7e/125a and miR-125a alone in BM cells from C57BL/6 mice. Overexpression of the 
miR-cluster or miR-125a dramatically increased day-35 CAFC activity and caused severe 
hematopoietic phenotypes upon transplantation. We showed that a single member of the 
miR-cluster, namely miR-125a, is responsible for the majority of the observed miR-cluster 
overexpression effects. Finally, we performed genome-wide gene expression arrays and 





HSCs sustain lifelong blood production, and are characterized by their self-renewal capacity 
and multilineage differentiation potential. HSCs give rise to progenitors that differentiate into 
the various blood cell types. Many characteristics of the hematopoietic stem and progenitor 
cell (HSPC) compartment display mouse strain-dependent genetic variation. For example, 
compared with C57BL/6 (B6) mice, DBA/2 (D2) mice have a higher HSPC frequency and 
cycling rate.1-4 The variation between these inbred mouse strains can be exploited to identify 
potential modulators of such HSPC traits. Useful in this respect has been the generation of 
BXD recombinant inbred mouse strains.5,6 Each of these strains represents a unique, but stable, 
genetic mosaic of B6 and D2 alleles. By making use of these strains, variation in many different 
HSPC traits has been mapped to genomic regions (reviewed in Gerrits et al7). Previously, we 
analyzed mRNA expression variation in developmentally related cell types isolated from the 
BXD mouse panel.8,9 In those studies, we identified groups of genes that were differentially 
expressed across mouse strains and therefore potentially causal for the variation in HSPC traits.
MicroRNAs are evolutionary conserved small (~22-nucleotide) noncoding RNAs that 
fine-tune gene expression by base-pairing with target mRNAs, leading to mRNA destabilization 
or translational repression.10-12 Each microRNA can coordinately target hundreds of different 
mRNAs,13 and each mRNA can harbor multiple microRNA target sites, creating complex 
microRNA/mRNA regulatory circuitries. A growing body of evidence has implicated specific 
microRNAs in the regulation of HSPC fate. For example, miR-181, miR-150, and the miR-17~92 
cluster have proven to be essential for lymphoid development,14-18 miR-223 for myeloid 
development,19,20 and miR-155 for both lymphoid and myeloid development.21-23 Dysregulated 
expression of these and other microRNAs has been shown to contribute to the pathogenesis 
and progression of hematologic malignancies.24,25
To determine whether the variation in gene expression and HSPC traits across mouse 
strains could be due to natural variation in microRNA expression, we initiated a genome-wide 
microRNA expression study of Lin-Sca-1+c-Kit+ (LSK), Lin-Sca-1-c-Kit+ (LS-K+), erythroid and 
myeloid cells isolated from B6 and D2 mice. We identified both cell type-dependent and mouse 
strain-dependent microRNAs. Interestingly, we discovered an evolutionary conserved cluster 
of microRNAs (99b/let-7e/125a) that is most highly expressed in HSPCs and that is differentially 
expressed between mouse strains. To assess whether the differential expression of members of 
this cluster could be functional, we overexpressed both the entire miR-cluster 99b/let-7e/125a 
and miR-125a alone in HSPCs, and found that this conferred an initial competitive advantage 
to these cells. However, we also found that mice reconstituted with these cells developed 
myeloproliferative neoplasms (MPNs). Our data suggest that miR-125a is responsible for the 
majority of the hematopoietic effects observed for the entire miR-cluster 99b/let-7e/125a. 
Finally, we identified the candidate functional downstream targets through which miR-125a may 
be able to modulate HSPC fate.




Mice. Female B6 (CD45.2) and D2 mice were purchased from Harlan and housed under clean 
conventional conditions. Female and male B6.SJL (CD45.1) mice were bred at the Central Animal 
Facility of the University of Groningen. All animal experiments were approved by the Groningen 
University Animal Care Committee.
Cell purification. BM cells were flushed from the femurs and tibias of 3 to 5 mice and pooled. 
Nucleated cells were stained with a panel of Alexa Fluor 700 (A700)-labeled lineage-specific 
Abs, FITC-labeled anti-Sca-1, PE-labeled anti-c-Kit, PE-cyanine-7 (PE-Cy7)-labeled anti–TER-119, 
and allophycocyanin- labeled anti–Gr-1. Abs were purchased from BioLegend. Triplicates were 
generated for each of the 8 conditions (4 cell types, 2 mouse strains).
MicroRNA expression analysis. Total RNA was isolated using the miRNeasy Mini Kit (QIAGEN) 
in accordance with the manufacturer’s protocol. Total RNA (100 ng) was labeled and hybridized 
to Agilent 8X15K Mouse miRNA arrays. Labeling, hybridization, and washing were performed by 
Oxford Gene Technology using the Agilent Mouse microRNA Microarray Kit. Data were extracted 
using Agilent Feature Extraction Software (Version 9.5.3.1). Data were thresholded at 1, log2-
transformed, and normalized to the 75th percentile using GeneSpring GX11.0 (Agilent). On the 
basis of principal component analysis, 1 sample was removed from further analysis. The starting 
dataset represented 577 noncontrol probes. False positives were excluded by only pursuing with 
those probes that were flagged as present in at least 2 of 3 replicates in any 1 of 8 conditions. The 
quality-filtered expression values were median-centered per microRNA and clustered (Euclidean 
distance, complete linkage) using Genesis.26 Two-way ANOVA was applied to identify cell type-
dependent and mouse strain-dependent microRNAs. A Benjamini-Hochberg false discovery rate 
correction was applied to control for multiple testing (P<.05). All microarray data are available for 
viewing on the Gene Expression Omnibus (GEO) under accession number GSE33691.
Retroviral vectors. Genomic DNA was isolated from B6 cells and a 1.2-kb region spanning the 
miR-99b, let-7e, and miR-125a stem loop sequences was amplified (forward primer: 5’-CCTCGA 
GTGGACTGAGGAGAATTGAGTGCAAG-3’, reverse primer: 5’-GCAATTGTGCCCTGAAGATCAG 
CAGGAAC-3’; Biolegio). The resulting PCR product was extracted from gel, TOPO-cloned into 
PCR4, cut from PCR4 using XhoI and MunI, and subcloned into the XhoI-EcoRI site of the MXW-
pPGK-IRES-EGFP vector, which is a murine stem cell virus-based vector with constitutively 
active PolII type promoter.27 The miR-125a vector was constructed from the miR-99b/let-
7e/125a vector by deleting the EcoRI-BstBI fragment (carrying the miR-99b/let7e segment of 
the miR cluster), followed by vector religation with an aliquot of random hexamers. The miR-155 
gene product and the MXW-pPGK-IRES-EGFP vector were a kind gift from Prof Chen (Stanford 
University School of Medicine, Stanford, CA). The miR-cluster 99b/let-7e/125a, miR-125a and 
miR-155 fragments were sequence verified (StarSeq; see supplemental Methods).
Retroviral overexpression of microRNAs in primary BM cells. Primary BM cells were isolated 
from B6 mice 4 days after IP injection of 150 mg/kg 5-fluorouracil (Pharmachemie Haarlem), 




recombinant mouse SCF (rmSCF; Peprotech), 20 ng/mL rmIL11 (R&D Systems), 1 ng/mL Flt3 
ligand (Amgen), penicillin, and streptomycin. BM cells were transduced by transfecting 
Phoenix ecotropic packaging cells with 1-2 µg of pDNA (MXW empty vector, MXW-miR-cluster 
99b/let-7e/125a, MXW-miR-125a, and MXW-miR-155) and 3-6µL of Fugene HD (Roche). Virus-
containing supernatant harvested 48 and 72 hours later was used to transduce 4-6x105 BM 
cells per 3.5-cm well. Three independent transductions were performed per condition per 
experiment. Five days after the first transduction, viable (negative for propidium iodide) EGFP+ 
cells were collected and tested in in vitro assays and collected in RNA lysis buffer (QIAGEN) for 
gene expression studies. Nonsorted cells were tested in an in vivo BM transplantation setting.
Quantitative PCR validation. We converted selected microRNAs to cDNA using the TaqMan 
MicroRNA Reverse Transcription Kit (Applied Biosystems). Next, real-time PCR with TaqMan 
MicroRNA assays (Applied Biosystems) was performed using the iCycler system (Bio-Rad). 
The following assays were used: hsa-miR-99b, hsa-let-7e, hsa-miR-125a-5p, mmu-miR-155, and 
snoRNA202. The comparative delta-delta Ct approximation method was used to analyze relative 
changes in gene expression.28 Each of the 3 samples was analyzed in triplicate and normalized 
to the endogenous control snoRNA202.
CAFC assays. The cobblestone-area forming cell (CAFC) assay was performed as previously 
described.29,30
Primary BM transplantation. BM cells were transplanted into lethally irradiated recipients 
without prior sorting for EGFP expression. Two independent transplantation experiments were 
performed, where B6 and B6.SJL mice were exchangeably used as a source of donor cells or 
transplant recipients. In both experiments, 9 mice (3 independent transductions x 3 mice) received 
transplants per condition with 5-10x106 cells each. On a 4- to 6-week basis posttransplantation 
blood analyses were performed. Blood cell numbers were counted using a Medonic hematology 
analyzer (Boule Medical). Subsequently, cells were stained with PE-labeled anti-CD45.2, Pacific 
Blue-labeled anti-CD45.1, allophycocyanin-Cy7–labeled anti–Gr-1, PE-Cy7-labeled anti-CD11b, 
Pacific Orange-labeled anti-CD45R/B220 (Invitrogen, Caltag Laboratories), and allophycocyanin-
labeled anti-CD3ε. Abs were purchased from BioLegend, unless otherwise specified. Data were 
acquired using an LSR II (BD Biosciences) and analyzed using FlowJo software (TreeStar). At the 
time of sacrifice, the peripheral blood, BM, spleen, liver, and in a few instances, lung tissues were 
analyzed. Cell counts, cytospin preparations, and FACS stainings were performed. Cells were 
stained using the aforementioned Abs mix or stained with lineage cocktail (A700-labeled anti-
Mac1, A700-labeled anti-Gr-1, A700-labeled anti-TER-119, A700-labeled anti-CD3ε, A700-labeled 
anti-B220), PE-labeled anti-cKit, Pacific Blue-labeled anti-Sca-1, PE-Cy7-labeled anti-CD150 and 
A647-labeled anti-CD48. Cytospins were stained with May-Grunwald-Giemsa (MGG).
Secondary BM transplantation. EGFP+CD45.2+ BM cells from the primary miR cluster and empty 
vector mice received transplants in competition with freshly isolated wild-type CD45.1+ BM cells 
in lethally irradiated recipients (CD45.2) at 4:1 (test to freshly isolated) ratios. For each of the 
conditions, 15 mice (3 individual primary mice x 5 secondary mice) received transplants with a total 
of 5x106 cells each. Blood analyses were performed on a 4- to 6-week basis posttransplantation.
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Downstream target analysis. Genome-wide gene expression was profiled in BM cells transduced 
with empty vector, miR-cluster 99b/let-7e/125a, miR-125a, and miR-155. Heterogeneous 
populations of viable EGFP+ BM cells were FACS-purified without any additional marker selection 
at 5 days after the first transduction (the exact time point at which the aforementioned in vitro and 
in vivo assays were initiated). All samples were analyzed in triplicate. Total RNA was isolated using 
the RNeasy Mini Kit (Qiagen). RNA was amplified using the Illumina TotalPrep RNA Amplification 
Kit (Ambion/Applied Biosystems) and hybridized to Sentrix MouseWG-6 Version 2.0 expression 
beadchips (Illumina) according to the manufacturer’s instructions. Hybridization and washing 
were performed by our in-house Genome Analysis Facility. Scanning was carried out on the 
iScan System (Illumina). Data were extracted using GenomeStudio software (Illumina), without 
normalization or background subtraction. Data were thresholded at 1, log2- transformed, and 
quantile normalized using GeneSpring GX11.0 (Agilent). The starting dataset represented 45.281 
probes. False positives were excluded by only pursuing with those probes that were flagged as 
marginal or present in all replicates in any 1 of 4 conditions (default detection P values cutoff 
0.8 for present and 0.6 for absent were used for flags). Predicted (conserved) downstream 
microRNA targets were imported from the TargetScan database.31
URLs. All raw data were deposited in the NCBI Gene Expression Omnibus (GEO, http://www.
ncbi.nlm.nih.gov/geo/, accession number GSE33691). All processed microRNA expression data 
on the 4 cell types from B6 and D2 mice were deposited on HemDb (http://hemdb.org/).
RESULTS
Identification of cell type-dependent microRNA signatures. To identify cell type-
dependent and mouse strain-dependent microRNAs in the hematopoietic system, we started 
a microarray-based microRNA profiling study of 4 developmentally related hematopoietic cell 
types isolated from the BM of B6 and D2 mice. We hybridized total RNA isolated from purified 
LSK multilineage cells, committed LS-K+ cells, erythroid TER-119+ cells, and myeloid Gr-1+ cells 
(Figure 1A) to Agilent microRNA arrays and evaluated microRNA expression levels. In total, we 
analyzed 23 samples representing 4 different cell types and 2 different mouse strains. Of the 
577 microRNAs profiled, 147 were expressed in at least 1 of these 8 conditions. To study the 
relationship between the samples, as well as the underlying patterns of microRNA expression, 
we applied an unsupervised 2-way hierarchical clustering method using the 147 quality-filtered 
microRNAs. This analysis showed that the cell-type effect greatly exceeded the mouse strain 
effect (Figure 1B top tree), and revealed 8 distinct microRNA signatures (Figure 1B left tree; 
supplemental Table 1). Of special interest is signature I consisting of microRNAs that are most 
highly expressed in LSKs and down-regulated upon differentiation. Signature I consists of miR-
125a-5p, miR-125b-5p, miR-126-3p, miR-130a, miR-155, miR-181d, miR-196b, miR-203, miR-222, 
miR-31, miR-99a, miR-99b, and let-7e. Considering their expression pattern, these microRNAs 
may represent important factors that keep cells from leaving the stem cell state. Signature II 
consists of microRNAs that are most highly expressed in LS-K+ cells, signatures III and IV are 
specific to erythroid cells, and signatures VI and VIII to myeloid cells. Signature VII consists 




of microRNAs that are important for lineage specification, commitment, and differentiation. 
Finally, signature V does not show a clear expression preference. We confirmed well-known 
cell-type-specific microRNAs: eg miR-196b in signature I,32 miR-451 in erythroid signature III,33 
and miR-223 in myeloid signature VIII.19,20 The entire microRNA expression dataset is available 
online (supplemental Table 1 and in GEO [accession number GSE33690]), and queries for 
specific micro-RNAs can be done on www.hemdb.org.
Identification of mouse strain-dependent miR-cluster 99b/let-7e/125a. An analysis of 
variance (2-way ANOVA, corrected P<.05) yielded 131 differentially expressed microRNAs, all of 
which showed a cell-type effect and of which 15 also showed a mouse strain effect (Figure 1C, 
supplemental Table 1). In total, 4 of the 15 mouse strain-dependent microRNAs were present 
in signature I, namely miR-125a, miR-125b, miR-130a, and miR-99b. They were all most highly 
expressed in the primitive cell compartment and down-regulated upon differentiation and 
generally higher expressed in D2 cells compared with B6 cells. These 2 criteria qualify those 
microRNAs as potential candidates regulating HSPC traits. Interestingly however, 2 of these 4, 
miR-125a and miR-99b are part of an evolutionary conserved microRNA cluster that is localized 
on chromosome 17: miR-cluster 99b/let-7e/125a (Figure 1D). The third member of this cluster, 
let-7e, shows an expression pattern comparable with the other 2 members (Figure 1E), but its 
strain effect did not reach statistical significance (corrected P=.064). In addition, miR-125b is 
present in 2 paralogous microRNA clusters that are located on chromosomes 9 and 16 (Figure 1F). 
The chromosome 9 cluster consists of miR-100, let-7a, and miR-125b-1 and the chromosome 16 
cluster consists of miR-99a, let-7c, and miR-125b-2. Although not all microRNA cluster members 
display a significant mouse strain effect, they all follow the same expression trend across cell 
types and mouse strains (Figure 1G). This view corroborates previous observations that proximal 
pairs of microRNAs (separated by < 50 kb) are generally coexpressed across tissues.34
Overexpression of miR-cluster 99b/let-7e/125a or miR-125a alone retains HSPCs in a 
primitive state. To assess whether differential expression of members of the 99b/let-7e/125a 
microRNA cluster could have functional consequences for HSPCs, and could be causal for 
the phenotypic differences between HSPCs from B6 and D2 mice, we performed gain-of-
function studies. We cloned the entire 99b/let-7e/125a cluster, as these 3 microRNAs showed 
coordinated expression, and miR-125a alone in a retroviral vector (both in its natural genomic 
context) (Figure 2A). MiR-155, known to affect HSPC characteristics, was included as a positive 
control.21 The miR-cluster 99b/let-7e/125a, miR-125a, and miR-155 were overexpressed in 
BM cells from 5-FU–treated mice. Transduced cells were sorted and overexpression of the 
individual members of miR-cluster 99b/let-7e/125a and miR-155 was validated using quantitative 
PCR (Figure 2B). Engineered expression levels of miR-cluster 99b/let-7e/125a members were 
substantially increased (1000-, 2-, 1500-fold, respectively) compared with the natural situation, 
in which members of the miR-cluster are on average 2-fold higher expressed in D2 than in B6 LSK 
cells (microarrays and quantitative PCR; data not shown). Concurrently, transduced EGFP+ cells 
were used to initiate CAFC, a surrogate in vitro assay to quantify the number of HSPCs. In this 
assay, early appearing cobblestones (day 7) are considered to represent progenitors and late-
appearing cobblestones (day 35) are considered to represent stem cells.29,30 Day-7 CAFC activity 
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Figure 1. Genetic screen identifies cell type- and mouse strain-dependent microRNAs. (A) MicroRNA 
expression was evaluated in 4 developmentally related cell types isolated from the BM of C57BL/6 and 
DBA/2 mouse strains. (B) Hierarchical clustering was performed using the 147 quality-filtered probes 
(Euclidean distance, complete linkage). Samples are in columns, microRNAs in rows. For each probe, 
data were median-centered, with the lowest and highest intensity values in blue and red, respectively. Of 
each of the 8 microRNA signatures the average expression across cell types and mouse strains is shown 
(y-axis represents log2 expression ranging from 4 to 8). The number in the graphs indicates the number of 
microRNAs per signature. (C) Venn diagram showing the number of differentially expressed microRNAs 




miR-99b, let-7e, and miR-125a, located on mouse chromosome 17. (E) Expression of miR-cluster 99b/
let-7e/125a members across cell types and mouse strains (axes: as in panel B). Shown is the mean± SD. 
(F) Paralogous microRNA clusters on chromosomes 9 and 16. (G) Expression of miR-100, miR-99a, 
and miR-125b across cell types and mouse strains (axes: as in panel B). For miR-125b only the cumulative 
expression of the chromosome 9 and 16 cluster could be assessed. Expression of let-7a and let-7c is not 
shown, as only the cumulative expression from multiple different genomic locations (including other 
chromosomes than 9, 16, and 17) could be assessed. Shown is the mean± SD. LT indicates long-term; ST, 
short-term; CMP, common myeloid progenitor; MEP, megakaryocyte-erythrocyte progenitor; and GMP, 
granulocyte-macrophage progenitor.
showed no differences between the control and microRNA-overexpressing cells. However, at 
day 35, a striking difference in the number of CAFCs was observed. The miR-155-overexpressing 
cells gave ~15-fold more CAFCs, whereas the miR-cluster 99b/let-7e/125a-overexpressing cells 
yielded a striking ~6.500-fold more CAFCs (Figure 2C left). Direct comparison between miR-
cluster 99b/let-7e/125a and miR-125a alone revealed very similar CAFC activity profiles and no 
significant differences were observed between these 2 overexpression conditions. Both the 
miR-cluster 99b/let-7e/125a and miR-125a strongly increased day-35 CAFC activity (Figure 2C 
right). Moreover, for both the miR-cluster and miR-125a, a substantial amount of CAFC activity 
remained even up until day 70 (data not shown).
To summarize, BM cells overexpressing miR-cluster 99b/let-7e/125a, miR-125a, or miR-155 
showed increased stem cell activity as measured by day-35 CAFC activity. These data suggest 
that overexpression of miR-cluster 99b/let-7e/125a or miR-125a alone retains cells in a 
primitive state. 
Sustained expression of miR-cluster 99b/let-7e/125a or miR-125a in HSPCs provides 
a competitive advantage, but also results in MPNs. We next assayed the microRNA-
overexpressing cells in a long-term competitive repopulation experiment in vivo. To achieve 
this, miR-cluster 99b/let-7e/125a, miR-125a alone and miR-155 were overexpressed in BM cells 
derived from 5-FU-treated mice and nonsorted cells were transplanted into lethally irradiated 
recipients. At 10 weeks posttransplantation, blood cell counts revealed a significant decrease 
in RBC numbers and a slight decrease in white blood cell (WBC) numbers for mice transplanted 
with miR-cluster 99b/let-7e/125a or miR-125a–overexpressing cells. However, whereas platelet 
counts were significantly decreased in miR-cluster reconstituted mice, this was not observed 
for miR-125a reconstituted mice. Recipients transplanted with miR-155 transduced cells showed 
a less dramatic decrease of RBC counts with no effect on WBC and platelet counts (Figure 3A). 
At this point in time, chimerism was assessed by quantifying the percentage of EGFP+ cells 
within the donor fraction. Whereas within 10 weeks the chimerism levels of the control mice 
remained relatively stable at 36%, those of the miR-155 mice increased from 15% to 45%, and 
those of the miR-cluster 99b/let-7e/125a and miR-125a mice increased from 25% or 10%, 
respectively, to 90%. This indicates that in the latter 3 cases the microRNA-transduced cells 
had a competitive advantage over the nontransduced cells (Figure 3B). Detailed FACS analyses 
revealed that the EGFP+ cells in both the miR-cluster 99b/let-7e/125a and miR-125a mice were 
enriched for granulocytes/macrophages (defined as being Gr-1+ and/or Mac-1+) at the expense 
of the number of B lymphocytes (B220+; Figure 3C). Clearly, hematopoiesis was disturbed in 
MICRORNA CLUSTER 99b/let7e/125a REGULATES HSPCs
3
47
Figure 2. Overexpression of miR-cluster 99b/let-7e/125a or miR-125a alone fixes HSPCs in a primitive 
state. (A) Schematic presentation of the retroviral vectors used to overexpress miR-cluster 99b/let-
7e/125a, miR-125a and miR-155. (B) Quantitative RT-PCR data showing the expression levels of the miR-
cluster 99b/let-7e/125a members and miR-155 on overexpression relative to the endogenous control 
snoRNA202. Shown is the mean ± SD. (C) CAFC data showing the number of HSPCs.
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these mice, resulting in lethality of some of the recipients (Figure 3D). In 1 of 2 independent 
transplantation experiments, 6 of 9 miR-cluster 99b/let-7e/125a-overexpressing mice died 
between 6-30 weeks posttransplantation. In the other transplantation experiment, despite 
strongly disturbed hematopoietic homeostasis of miR-cluster 99b/let-7e/125a and miR-125a 




Figure 3. Sustained expression of miR-cluster 99b/let-7e/125a or miR-125a alone disturbs 
hematopoiesis. (A) WBC, RBC, and platelet counts at 10 weeks after transplantation (n=9-18 mice/
group). P values (*.01<P<.05; ***P <.001) are displayed (Mann-Whitney test). (B) Chimerism levels were 
assessed at 10 weeks after transplantation by analyzing the percentage of EGFP+ cells in the donor fraction 
(n=9-18 mice/group). The arrows indicate the increase in chimerism levels over the first 10 weeks after 
transplantation. (C) Cell-type distribution in the blood as assessed by FACS (n=9-18 mice/group). Shown is 
the mean ± SEM (D) Survival of mice (n=9-18 mice/group). The gray box indicates the time point analyzed 
in the other panels. WBC indicates white blood cells; RBC, red blood cells; PLT, platelets; GM, granulocytes/
















































Competitive advantage provided by miR-cluster 99b/let-7e/125a decreases over time. To 
quantify the number of HSPCs in the BM compartments of the nonmorbid miR-cluster 99b/let-
7e/125a mice and their empty vector controls, CAFC assays on EGFP+ BM cells were performed. At 
21 weeks posttransplantation, the miR cluster-transduced cells still exhibited more day-35 CAFC 
activity compared with empty vector-transduced cells (Figure 5A). However, it should be noted 
that the fold increase in day-35 CAFC activity of miR-cluster 99b/let-7e/125a-overexpressing 
cells dropped from ~6.500 before transplantation to ~400 in this 21-week time frame in vivo. 
Reduction of the stem cell pool was also suggested by immunophenotypic analyses of the 
primitive BM compartment. We observed a reduced frequency of EGFP+ primitive stem cells 
in the BM, defined as Lin-Sca-1+c-Kit+CD48-CD150+ cells, in miR-cluster 99b/let-7e/125a mice 
compared with empty vector mice 5 months after transplantation (Figure 5B-C). 
To assess the quality of the HSPCs in the BM compartments of the miR-cluster 99b/let-7e/125a 
and empty vector mice, we performed secondary BM transplantations. We evaluated the 
in vivo repopulating ability of EGFP+ cells isolated from the BM of the primary recipients by 
transplanting them in competition with freshly isolated BM cells. Whereas miR-cluster 99b/
let-7e/125a-overexpressing cells continued to show disturbed hematopoietic homeostasis, 
reflected by myeloproliferation in the peripheral blood at the expense of the number of B 
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lymphocytes (Figure 5D), their initial competitive advantage was lost. No differences in EGFP+ 
donor cell chimerism were observed between miR-cluster 99b/let-7e/125a and empty vector 
mice 6 weeks or 24 weeks after transplantation (Figure 5E).
To summarize, our data indicate that miR-cluster 99b/let-7e/125a indeed affects HSPC 
traits. We found that overexpression of this microRNA cluster conferred an apparent initial 
competitive advantage to engrafting hematopoietic cells in an in vivo transplant setting.
In search of functional miR-125a targets. To understand the molecular mechanisms by which 
miR-cluster 99b/let-7e/125a, and more specifically miR-125a, is able to modulate HSPC fate, it is 
essential to identify genes regulated by these microRNAs. To address this question, we analyzed 
Illumina WG6 gene expression arrays from EGFP+ cells transduced with empty vector, miR-cluster, 
miR-125a and miR-155 (included as a control again). Of the 45.281 probes on the array, 28.977 were 
expressed in at least 1 of the 4 conditions (empty vector, miR-cluster, miR-125a, and miR-155). For 
microRNA target prediction, we used one of the most widely used algorithms, namely TargetScan. 
It predicts 48, 712, and 572 evolutionary conserved targets for miR-99b, let-7e, and miR-125a, 
respectively.31 To refine the list, only those targets were selected whose expression reacted on 
changing microRNA expression levels. In the list of quality-filtered probes (28.977), we identified 
912 predicted targets of the entire miR-cluster 99b/let-7e/125a, including 485 specific for miR-125a, 
and 164 targets of miR-155. We then visualized the expression levels of these predicted targets on 
overexpression of the miR-cluster 99b/let-7e/125a and miR-155 (Figure 6A). This analysis showed 
that the expression of most of the predicted miR-cluster 99b/let-7e/125a targets was indeed 
mildly affected in the miR-cluster-transduced cells, but not in the miR-155–transduced cells. In 
contrast, most of the miR-155 targets were only affected in the miR-155-transduced cells, but 
not in the miR-cluster-transduced cells. The entire gene expression dataset is available online 
(supplemental Table 2) and in GEO (accession number GSE33689).
Because our in vitro CAFC activity and in vivo transplantation data indicate that miR-125a is 
responsible for the majority of the miR-cluster 99b/let-7e/125a-induced phenotypes, we restricted 
our search for downstream targets to only miR-125a. From the list of predicted miR-125a targets 
(485, identified using Target Scan), we subsequently selected those probes that were at least 
1.5-fold differentially expressed and consistently down-regulated upon overexpression of both 
miR-cluster 99b/let-7e/125a and miR-125a. This resulted in 45 probes representing 40 genes that 
qualify as candidate functional targets (Table 1). We classified these 40 potential targets using Gene 
Ontology functional annotations for biological processes. Annotated categories were grouped 
as illustrated in Figure 6B (supplemental Table 3). Among these groups were cell proliferation, 
differentiation, and apoptosis. Seven potential miR-125a targets categorized as apoptosis related. 
Interestingly, among them was Bak1, a proapoptotic gene previously suggested by Guo et al as a 
miR-125a target. Guo et al showed that miR-125a overexpression phenotypes may be mediated via 
anti-apoptotic effects.35 This suggests that protection against apoptosis may have been at least 
partially responsible for the phenotypes that we observed on miR-cluster 99b/let-7e/125a and 
miR-125a overexpression. However, because enhanced differentiation and lineage skewing were 
observed in our in vivo transplantations, genes involved in cell proliferation and differentiation 
may be of importance to explain the full spectrum of effects caused by these microRNAs. Future 

































































Figure 4. Sustained expression of miR-cluster 99b/let-7e/125a induces MPNs with occasional 
progression to leukemia. (A) PB WBC counts for empty vector, miR-cluster 99b/let-7e/125a, and miR-155 
mice at time of sacrifice. Closed/black squares represent nonmorbid miR-cluster mice, whereas open/red 
squares represent moribund miR-cluster mice. L indicates leukemic mouse. (B) Photographs of femur and 
tibia bones, BM cellularity (representing 2 femurs, 2 tibias and pelvic bones) and spleen weight for empty 
vector, miR-cluster 99b/let-7e/125a and miR-155 mice at time of sacrifice. Closed/black squares represent 
nonmorbid miR-cluster mice, whereas open/red squares represent moribund miR-cluster mice. P values 
(*.0< P <.05; **.001< P <.01) are displayed (Mann-Whitney test). L indicates leukemic mouse. (C) Percentage 
EGFP+ cells in PB, BM, and spleen (n=5 for EV, n=6 for CLUS, n=3 for 155). Nonmorbid and moribund miR-
cluster 99b/let-7e/125a mice showed similar percentages and were therefore combined. Shown is the 
mean ± SEM. (D) Cell-type distribution in PB, BM, and spleen of empty vector, miR-cluster 99b/let-7e/125a, 
and miR-155 mice as assessed by FACS. Shown is the mean ± SEM. Data for nonmorbid and moribund 
mice are shown separately for PB (n=5 for EV, n=3 for nonmorbid [N] CLUS, n=3 for moribund [M] CLUS, 
n=3 for 155) and combined for BM and spleen (n=5 for EV, n=6 CLUS, n=3 for 155), because the cell-type 
distributions between these mice differed in PB, but not in BM and spleen. (E) Representative MGG-stained 
cytospin preparations from BM and spleen cells. For the miR-cluster 99b/let-7e/125a, 2 pictures are shown: 
1 representative of a nonmorbid mouse (N) and 1 of the leukemic mouse (L).
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Figure 5. Effects of sustained expression of miR- cluster 99b/let-7e/125a on the stem cell compartment. 
(A) CAFC data showing the number of HSPCs in the EGFP+ BM fraction of 3 individual empty vector and 
(nonmorbid)  miR-cluster  99b/let-7e/125a  mice  at ~21 weeks posttransplantation. (B) Frequency of 
LT-HSCs (Lin-Sca-1+c-Kit+CD48-CD150+) per 1x106 EGFP+ BM cells at 21 weeks posttransplantation. Analyses 
were performed using FlowJo software (TreeStar), followed by quantification of the number of LT-HSCs 
(n=3/group, same mice as described in panel A). Shown is the mean ± SEM. (C) Representative FACS plots of 
the EGFP+ primitive BM compartment at 21 weeks after primary transplantations. (D) Cell-type distribution 
in the blood of empty vector and miR-cluster 99b/let-7e/125a mice upon secondary transplantations 
as assessed by FACS at 24 weeks posttransplantation. Shown is the mean ± SEM (n=15 mice/group). (E) 
Chimerism levels at 6 and 24 weeks after secondary transplantation (n=15 mice/group). GM indicates 
granulocytes/macrophages; B, B lymphocytes; T, T lymphocytes; and O, other cell types.
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Table 1. Candidate functional miR-125a targets.
Gene Symbol Fold Change
Gene Ontology category
1 2 3 4 5 6 7 8
Mtf1 -5.11 x
Alpk3 -4.36 x
Mapk8ip1 -3.92 x x x x




Ets1 -3.4 x x x x
Taf9b -3.12 x x x
Cramp1l -3.11 x
Enpep -3.09 x
Ache -3.01 x x
Bmpr2 -2.98 x x x





Ece1 -2.58 x x
Tle3 -2.46 x x x
Ubn1 -2.4 x
Cdr2l -2.38 x





Pafah1b1 -2.02 x x x
Abcc5 -1.91 x
Bak1 -1.87 x x x x x x
Coro2a -1.83 x
Cdc42se1 -1.8 x x








Fold change: down-regulation upon miR-125a overexpression compared to empty vector. Gene Ontology (GO) categories: 
1. Apoptosis/Cell death, 2. Proliferation, 3. Differentiation, 4. Chromatin/DNA/RNA, 5. Signal Transduction/Pathways, 6. Protein/Enzymes, 
7. Transport, 8.Other (not assigned to category 1-7).
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Figure 6. Identification of candidate functional miR-125a targets. (A) Visualization of expression of 
all quality-filtered predicted miR-cluster and miR-155 targets in miR-cluster-transduced and miR-155-
transduced cells. Shown are MvA plots comparing 2 samples. The log2 ratio of each probe (expression 
difference) is plotted versus the log2 mean for each probe. The red lines represent the best fit to the data. 
In these plots, the predicted targets that are shared between the miR-cluster and miR-155 are not displayed. 
(B) Venn diagram showing the identified candidate miR-125a targets down-regulated upon miR-cluster 
99b/let-7e/125a or miR-125a overexpression. The intersection represents 40 genes that were consistently 
1.5-fold down-regulated upon miR-cluster 99b/let-7e/125a and miR-125a overexpression. These 40 genes 
were assigned according to Gene Ontology (GO) biological process categories. Genes assigned to common 
GO categories were grouped together (supplemental Table 3). The pie chart shows relative distributions of 
grouped GO categories. The size of the sectors in the pie chart was defined based on the number of genes 
assigned to the category (in redundant fashion). Genes not assigned to any of the defined categories1-7 were 
defined as Other.8 Gene Ontology analyses were performed using GOAL software.40
DISCUSSION
In this report, we set out to determine whether the observed natural variation in HSPC traits 
across the genetically distinct mouse strains B6 and D2 could be due to natural variation in 




erythroid and myeloid cells isolated from B6 and D2 mouse strains, and detected natural variation 
in microRNA expression between these 2 mouse strains. Of special interest was an evolutionary 
conserved miR-cluster located on chromosome 17 consisting of miR-99b, let-7e, and miR-125a. All 
cluster members were most highly expressed in LSKs and down-regulated upon differentiation 
and generally higher expressed in D2 cells compared with B6 cells. We found that overexpression 
of miR-cluster 99b/let-7e/125a or miR-125a alone conferred an apparent competitive advantage 
to HSPCs, but also that these cells exhibited increased myeloid differentiation, ultimately 
leading to the development of MPNs in mice reconstituted with these cells. Loss of competitive 
advantage following serial transplantation suggests that in the long-term disturbed homeostasis 
may lead to HSPC exhaustion. Finally, as miR-125a was shown to be responsible for the majority of 
the miR-cluster 99b/let-7e/125a overexpression phenotypes, we identified candidate functional 
targets through which miR-125a could modulate HSPC fate.
While we were performing our final experiments, Guo et al reported that miR-99b, let-7e, 
and miR-125a were enriched in long-term HSCs (LSK/CD34-/Flk2-) and that overexpression of 
miR-125a alone, but not miR-99b or let-7e, could amplify the HSC pool.35 This result was shown 
to be accomplished by decreasing the level of apoptosis in hematopoietic progenitors through 
targeting pro-apoptotic genes such as Bak1. We confirmed the down-regulation of Bak1 upon 
miR-cluster 99b/let-7e/125a and miR-125a overexpression, suggesting that decreased apoptosis 
of HSPCs may have contributed to the observed hematopoietic phenotypes. In line with this 
finding was the observed prolonged CAFC activity (day 70) and the initial in vivo competitive 
advantage in primary recipients, both observed for the miR-cluster and miR-125a-overexpressing 
cells. However, whereas Guo et al showed amplification of the HSC pool after sustained miR-125a 
overexpression, we reported a decline of the primitive BM compartment and loss of competitive 
advantage upon secondary transplantation. Because anti-apoptotic effects cannot explain 
these results, we suggest that additional parameters affecting proliferation and differentiation 
are contributing to the miR-125a-induced phenotypes. As several identified potential miR-125a 
targets are involved in cell proliferation and differentiation, it would be interesting to determine 
their role in miR-cluster 99b/let-7e/125a and miR-125a–mediated hematopoiesis.
Other reports have recently described effects of miR-125b, a paralog of miR-125a, on HSPCs. 
O’Connell et al36 and Bousquet et al37 reported that overexpression of miR-125b caused MPNs that 
progressed to a lethal acute myeloid leukemia or resulted in B/T-cell acute lymphoblastic leukemia. 
In addition, Bousquet et al provided evidence that miR-125b confers a proliferative advantage 
to leukemic cells,37 whereas O’Connell et al showed that miR-125b promotes hematopoietic 
engraftment of human HSCs.36 Finally, Ooi et al reported that overexpression of miR-125b in HSCs 
enhances their function and enriches for lymphoid-balanced and lymphoid-biased HSCs.38 They 
also described a skewing toward the lymphoid lineage in the peripheral blood of these mice, and 
that a small subset of them developed a lymphoproliferative disease. In addition, they identified 
Bmf and Klf13 as miR-125b downstream targets with a link to apoptosis. Whereas in our dataset 
we could not confirm down-regulation of Bmf, Klf13 was found to be down-regulated upon 
overexpression of miR-125a and therefore could be considered as a possible candidate.
It is interesting, yet confusing, to see that all the reports on the miR-125 family in HSCs describe 
distinct gain-of-function phenotypes (from no- to myeloid- to lymphoid malignancies). As 
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suggested by O’Connell et al, differences in overexpression levels may underlie these phenotypic 
differences.36 In addition, whereas miR-125a and miR-125b have identical seed sequences, the 
mature forms of these 2 microRNAs differ. Therefore, it needs to be experimentally validated 
whether miR-125a and miR-125b really do share the exact same targets.
The initial competitive advantage of miR-cluster 99b/let-7e/125a-overexpressing cells 
and its loss over time relates to the differences between B6 and D2 mice. First, hematopoietic 
recovery by B6 and D2 stem cells has been studied in competitive transplantation settings and 
has uncovered interesting kinetics. Whereas D2 hematopoiesis was predominant initially, it was 
eclipsed by B6 hematopoiesis over time.39 Second, 2.6% of B6 stem cells has been shown to 
be in S-phase of the cell cycle versus a striking 24% of D2 stem cells.3 Together, these findings 
indicate that the increased proliferation rate for D2 stem cells may have provided them with an 
initial competitive advantage, but that this increased cycling rate also made them exhaust more 
rapidly. We consider it plausible that the differential expression of miR-cluster 99b/let-7e/125a 
(and thus its targets) may at least be in part responsible for the observed variation in stem cell 
cycling and repopulation kinetics between B6 and D2 mouse strains.
Collectively, our data and other recent reports point to an important role for the miR-125 
family in hematopoiesis. To conclude, we uncovered the existence of natural variation in 
microRNA expression between mouse strains, and showed that this may contribute to the 
observed natural variation in HSPC traits. Yet, we were not able to identify any published HSPC 
traits that mapped to the here-reported locus containing miR-cluster 99b/let-7e/125a.7 We 
anticipate that future genetic studies will shed new light on how microRNAs modulate HSPC 
fate and on how they themselves are regulated.
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CHAPTER 4
ABSTRACT
Despite increasing knowledge on the regulation of hematopoietic stem/progenitor cell 
(HSPC) self-renewal and differentiation, in vitro control of stem cell fate decisions has been 
difficult. The ability to inhibit HSPC commitment in culture may be of benefit to cell therapy 
protocols. Small molecules can serve as tools to manipulate cell fate decisions. Here, we 
tested two small molecules, valproic acid (VPA) and lithium (Li), to inhibit differentiation. 
HSPCs exposed to VPA and Li during differentiation-inducing culture preserved an immature 
cell phenotype, provided radioprotection to lethally irradiated recipients, and enhanced in 
vivo repopulating potential. Anti-differentiation effects of VPA and Li were observed also at 
the level of committed progenitors, where VPA re-activated replating activity of common 
myeloid progenitors and granulocyte macrophage progenitors. Furthermore, VPA and 
Li synergistically preserved expression of stem cell-related genes and repressed genes 
involved in differentiation. Target genes were collectively co-regulated during normal 
hematopoietic differentiation. In addition, transcription factor networks were identified as 
possible primary regulators. Our results show that the combination of VPA and Li potently 
delays differentiation at the biologic and molecular levels and provide evidence to suggest 
that combinatorial screening of chemical compounds may uncover possible additive/





Hematopoietic stem/progenitor cells (HSPCs) have a great clinical potential, but many of their 
applications are limited by insufficient numbers. Therefore, attempts have been made to define 
culture conditions, which would amplify stem cells in an uncommitted state and maintain 
their potential in vivo.1-3 However, so far there has been limited success in preventing HSPC 
commitment and differentiation in vitro without genetic manipulation (eg, overexpression 
of HoxB4, Bmi1, β-catenin).4-6 Alternatively, small molecules could be used as new tools 
for manipulating cell fate decisions. A number of these compounds have been identified to 
affect developmental processes, stem cell self-renewal and differentiation, or reprogramming 
efficiency of somatic cells to a pluripotent state.3,7-11 Two of such molecules, valproic acid 
(VPA) and lithium (Li), have been shown to affect normal and malignant hematopoiesis.12,13 
VPA is a pleiotropic histone deacetylase (HDAC) inhibitor (HDI), which can modulate histone 
acetylation by preventing its deacetylation.8 During commitment and differentiation, the 
chromatin structure of stem cells undergoes major epigenetic changes, which affect cellular 
transcriptional programs. Therefore, factors interfering with chromatin remodeling enzymes, 
such as HDIs, might modulate the behavior of stem and progenitor cells.14,15 For instance, it 
has been suggested that VPA can enhance stem cell proliferation, while retaining self-renewal 
in ex vivo stem cell expansion protocols.16-18 Furthermore, several groups suggested that 
HDIs can affect multilineage differentiation of hematopoietic cells.19-22 The hematopoietic 
effects of Li have been described for the first time in psychiatric patients, which included 
disturbed differentiation into several lineages and increased numbers of CD34+ cells.13,23,24 
In vivo and in vitro studies with human and murine BM cells confirmed the stimulatory effects 
of Li on hematopoiesis.25,26 Furthermore, experimental findings suggest that Li can increase 
transplantable HSPCs in mice.25 Although the mechanism by which Li affects HSPCs is unclear, 
multiple molecular targets have been proposed, including glycogen synthase kinase 3β, 
a negative regulator of Wnt pathway.27 Wnt signaling, as well as epigenetic events, play an 
important role in control of HSPC fate decisions.6,14 Taken together, data suggest that VPA and 
Li might serve as chemical regulators of both stem cell maintenance and differentiation.
We hypothesized that combinations of small molecules might be useful to promote 
maintenance of HSPCs in culture by inhibiting cell commitment. In this study, the combined 
effects of VPA and Li on HSPC proliferation, differentiation, and self-renewal were investigated. 
We document potent synergistic effects of both chemical compounds in a variety of in vitro and 
in vivo assays and showed strong anti-differentiation activity at the level of uncommitted and 
committed progenitors. Moreover, we identified genetic networks and putative targets that 
are transcriptionally affected by both compounds. Our data support the notion that chemical 
compounds may be of use in ex vivo cell therapy protocols.
MATERIAL AND METHODS
Mice. Female B6.SJL (CD45.1) mice, originally purchased from The Jackson Laboratory and bred 
in our local animal facility, and female wild-type B6 (CD45.2) mice (Harlan) were used as a source 
of donor HSPCs. In the transplantation settings, we used female B6.SJL donors, female wild-type 
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B6 (Harlan) BM as competitors, and female F1:B6xB6.SJL (CD45.1/2) as recipients. All animal 
experiments were approved by the local animal ethical committee of the University of Groningen.
Stem/progenitor cell isolation. Mice were anesthetized and killed by cervical dislocation. 
Unfractionated BM cells were obtained by crushing femora, tibia, and pelvic bones. Cell 
suspensions were filtered through a 100µm cell strainer (BD Biosciences) to remove debris, 
and the cells were counted on a Medonic CA620 analyzer (A. Menarini Diagnostics). After 
erythrocyte lysis cells were stained with lineage cocktail (A700-Mac1, A700-Gr1, A700-Ter119, 
A700-CD3, A700- B220), Pacific Blue-Sca1, PE-ckit, FITC-CD34, and PECy7-CD16/32 (Biolegend). 
After staining, the cells were resuspended in propidium iodide (PI) solution (1µg/mL) and 
uncommitted (Lin-Sca1+ckit+ [LSK]) and committed (common myeloid progenitor [CMP], 
L-S-K+CD34+CD16/32mid; granulocyte macrophage progenitor [GMP], L-S-K+CD34+CD16/32high) 
hematopoietic stem/progenitor subpopulations were sorted by aMoFlo XDP cell sorter (Dako 
Cytomation).
Stem/progenitor cell differentiation. Freshly isolated uncommitted and committed 
hematopoietic progenitor subpopulations were differentiated in a liquid or semisolid medium 
in the presence of FCS (10% or 30% FCS, respectively), murine SCF (mSCF; 100 ng/mL; Amgen), 
and recombinant mGM-CSF (10 ng/mL or 20 ng/mL, respectively; R&D Systems). Cells in liquid 
cultures were plated at a density of 2000 cells/mL in a 6-well plate (Costar) and cultured in 
StemSpan medium (StemCell Technologies). Cells in semisolid medium were plated in various 
concentrations. The cells were cultured for 7 days at 37°C in a humidified atmosphere and 5% 
CO
2
 in air with or without 1mM VPA (Sigma-Aldrich) or 5mM LiCl (J.T.Baker), or the combination. 
Both compounds were dissolved in PBS solution (PAA Laboratories GmbH).
Cell analysis. After liquid cultures, cells were harvested; total cell number and cell viability were 
determined by trypan blue and/or PI exclusion. Cultured cells were centrifuged for cytospin 
preparations (800 rpm; Shandon cytospin III cytocentrifuge; Thermo Fisher Scientific BV,) and 
stained with May-Grunwald-Giemsa staining. Cytospins were analyzed with light microscopy 
by counting >200 cells per experimental condition. Cells were classified as immature (blast-
like) or differentiated on the basis of nucleus and cytoplasm morphology. To analyze the 
immunophenotype of 7-day differentiated LSK cells, cells were stained with a cocktail of Abs 
as described earlier and analyzed on the LSR-II (BD Bioscience). Data analyses were performed 
with FlowJo PC Version 7.6.5 software (TreeStar).
Clonogenic assays. The CFU assay was performed to assess the potential of cells to form 
granulocyte/macrophage colonies (CFU-GM). Briefly, either freshly isolated hematopoietic 
progenitor subpopulations or cells differentiated for 7 days were plated in a methylcellulose 
medium, and after 6 or 7 days colonies with granuloid and/or macrophage cells were scored. 
Colonies derived from single cells of freshly isolated progenitors were replated, and secondary 
GM colonies were scored after another 7 days of semisolid culture. To assess the number of 
hematopoietic progenitor cells or more primitive stem cells cobblestone area-forming cell 
(CAFC) assays were performed in the population of 7-day differentiated cells. Both assays were 




In vivo transplantation assays. Seven-day cultured cells (CD45.1) alone or mixed with 0.5x106 
of freshly isolated BM competitor cells (CD45.2) were injected into the retro-orbital sinus of 
lethally irradiated (9.5 Gy) mice (CD45.1/2). In transplantations without competitors, recovery 
of peripheral blood counts was determined up to 32 days by automatic cell counting of blood 
samples (Medonic CA620 analyzer). Long-term repopulation potential of cells transplanted in 
the presence of competitors was monitored by calculation of the percentage of CD45.1, CD45.2, 
and CD45.1/2-derived cells in the blood. Data were acquired with an LSR-II (BD Bioscience) and 
analyzed with FlowJo PC Version 7.6.5 software (TreeStar).
Gene expression analysis. Global gene expression was assessed in 7-day cultured cells (growth 
factor [GF] only, Li, VPA, Li+VPA). All samples were analyzed in independent biologic triplicates. 
Total RNA was isolated with the RNeasy kit (QIAGEN), according to manufacturer’s protocol. 
RNA concentration, quality, and integrity were measured with the Experion Automated 
Electophoresis System (Bio-Rad). RNA was amplified with the Illumina TotalPrep RNA 
Amplification Kit (Ambion/Applied Bioscience) and hybridized to Mouse Ref-8_V2 expression 
platform (Illumina) according to the manufacturer’s instruction. Scanning was performed 
on the iScan System (Illumina). Image analyses and extraction of raw expression data were 
performed with BeadStudio Version 3.2 software (Illumina) with default settings, no background 
subtraction, and no normalization. The raw data were threshold at 1, log2-transformed and 
quantile-normalized with the use of GeneSpring-GX11.0 (Agilent). From the starting probe list 
(25 697 probes) probes not expressed in any replicate of the 4 conditions were excluded. The 
filtered list represented 20586 probes. Probes differentially expressed between drug-treated 
and control sample (GFs only) were defined by Welch t test with Benjamini-Hochberg correction 
and false discovery rate <0.05. Next, a 1.5-fold differential expression cutoff was applied. Gene 
expression analyses of 4 distinct primary cell subsets (LSK, L-S-K+, Gr1+, Ter119+), as described 
previously,29 were used for comparison of VPA and Li effects with the physiologic hematopoietic 
differentiation program. Finally, data were subjected to relevance network analyses as 
described in Voy at al.30 Networks were visualized in Gephi Version 0.8 beta software with the 
use of the Yifan-Hu and Fruchterman-Reingold force-directed layout algorithm.31 All raw data 
were deposited in the NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) as 
accession number GSE34088.
ChIP assay. The ChIP assay was performed to determine histone acetylation at promoter 
regions of specific genes with the use of the method described by Frank et al.32  In brief, 
5x106 cells were fixed with 1% formaldehyde for 10 minutes at RT. After cell lysis, cross-linked 
chromatin was fragmented by sonication to obtain ~200- to 600-bp fragments. Precleared 
chromatin was precipitated with anti–acetyl-Histone4 (Millipore) Ab. The immunoprecipitated 
chromatin was washed subsequently with washing buffers.32 For reverse cross-linking, samples 
were incubated overnight at 65°C in 1% SDS, 0.1M NaHCO-containing buffer, followed by 
treatment with Rnase A (Roche) and proteinase K (Fermentas Gmbh). DNA was isolated by 
ethanol/chloroform/isopropanol precipitation. The promoter regions of genes of interest were 
amplified by quantitative PCR (Bio-Rad) with the use of gene-specific primer pairs for β-actin 
(fwd, GGCAGTGTCCACAAGGGCGG; rev, TTGAGGAAGAGGATGAAGAGTTTTGGCG), HoxA7 
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(fwd, GCCAGTCTTCCAGCATGGCCTG; rev, CTCTGCTGCCCAACGCTCTCTG), and HoxB4 (fwd, 
GGGAGGGGTAGAGAAGGGGAAATAAACC; rev, GCCACCCGGCCTGCGATTC).
RESULTS
VPA and Li preserve the immature phenotype of HSPCs during myeloid differentiation 
in vitro. In vitro differentiation cultures are a convenient model to study the effects of 
new compounds on cell proliferation and differentiation. Purified HSPCs, defined by a LSK 
phenotype, were differentiated into the granulocyte/macrophage lineage by stimulation with 
SCF and GM-CSF in the presence or absence of VPA with or without Li. After a 7-day liquid 
cultures the effect of both compounds on cytokine-induced HSPC differentiation was studied 
with respect to cell proliferation and differentiation.
The addition of Li, either alone or in combination with VPA, led to lower numbers of 
nucleated cells, whereas this effect was not observed on VPA exposure (Figure 1A). Despite 
decreased proliferation, the combination of VPA+Li resulted in a significantly higher proportion 
of viable cells as measured by PI exclusion, used as a marker for dead cells (Figure 1B). Because 
the cultures were initiated with purified LSK cells, after 7 days of differentiation Lineage, Sca-1, 
and c-kit marker expression was reanalyzed by flow cytometry. Combined drug treatment 
(VPA+Li) resulted in a significantly higher (8-fold) number of cells with a LSK phenotype 
compared with control cells grown with GFs only. On VPA exposure a 6-fold increase in number 
of phenotypically defined LSK cells was observed, whereas Li had only a marginal (1.5-fold) 
effect (Figure 1C-D). The immature cell phenotype as measured by flow cytometry was in the 
agreement with morphology of the cells (Figure 1E-F). Quantification of the percentage of cells 
with blast-like morphology showed that cells treated with VPA+Li contained 7.5-fold more cells 
with immature morphology. VPA treatment lead to a 4.5-fold increase, whereas the addition 
of Li resulted in only 2.5-fold more cells with blast-like morphology over control conditions 
(Figure 1E-F). These data indicate that VPA and Li treatment preserved the HSPC phenotype and 
morphology after strong differentiation-inducing cultures.
Enhanced in vitro functional potential of cells exposed to VPA and Li. To test whether cells 
exposed to VPA and Li retained stem/progenitor function, in vitro assays for hematopoietic 
cell activity were performed. Progenitor potential of 7-day cultured cells was determined with 
semisolid CFU assay, whereby cells were stimulated into granulocyte/macrophage colonies 
with GM-CSF and SCF. Cells treated with VPA alone or with a combination of VPA+Li gave rise 
to a higher number of colonies than control cells (45-fold and 81-fold more, respectively). 
However, treatment with Li did not significantly influence colony-forming capacity (Figure 2A). 
To test the functional activity of more primitive cells after 7 days of differentiation culture, we 
performed CAFC assays. In this assay, progenitor activity is measured by early appearing CAFCs 
(day-7) and stem cell activity by late appearing CAFCs (day 35). Cells exposed to the combination 
of both compounds (VPA+Li) showed a 30-fold increase in absolute numbers of early- and a 
3.5-fold increase in absolute numbers of late-appearing CAFCs (P<.05) compared with control 
cells (GFs only). Cells treated with VPA alone showed 7-fold and 2-fold more early and late CAFC 




Figure 1. Preserved immature phenotype of hematopoietic progenitor cells after in vitro myeloid 
differentiation culture. HSPCs (LSK cells) were differentiated in vitro into the myeloid lineage for 7 
days in the presence or absence of VPA and/or Li. (A) Effects of VPA+Li treatment on cell proliferation. 
The number of viable cells was scored with trypan blue exclusion. Shown is the mean ± SD (n = 5-7). (B) 
The proportion of cells that excludes PI after 7 days of differentiation culture. Shown is the mean ± SD 
(n = 5-7). The proportion of cells excluding PI was in agreement with the proportion of dead cells stained 
with trypan blue (data not shown). (C) Representative flow cytometric analysis of LSK expression on cells 
cultured for 7 days with or without VPA+Li. Cells in the graphs were pregated for viable (PI-) cells. An 
equal number of events were collected for each sample. (D) Absolute number of cells with preserved LSK 
phenotype, quantified on the basis of on FACS data, presented as number of LSK cell per well. Error bars 
represent SD of the mean (n = 3-7). (E) Percentage of cells with preserved blast-like morphology after 
7-day differentiation culture. Shown is the mean ± SD (n = 3-6). (F) Representative cell morphology of 
cells cultured with or without VPA+Li. Cytospin preparations were stained with May-Grunwald-Giemsa 
and viewed under a light microscope (original magnification X100). The differences between groups were 
evaluated by Welch t test, **P <.01 and ***P <.001.
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CAFC activity was observed (Figure 2B). As shown by these 2 independent assays, the in vitro 
functional potential of stem and progenitor cells was significantly enhanced by VPA and VPA+Li 
treatment, but the combination of both compounds most efficiently preserved HSPC function.
VPA and Li improve survival, blood cell recovery, and short-time engraftment after 
BM transplantation. To confirm the functional activity observed with in vitro assays, the in 
vivo reconstitution properties of cells differentiated in the presence of VPA and/or Li were 
examined. The progeny of 2000 LSK cells, cultured for 7 days with GM-CSF with or without 
VPA and Li, was transplanted into lethally irradiated mice. At days 10, 14, 21, 28, and 32 after 
transplantation survival and recovery of peripheral blood counts were analyzed. Mice that 
received a transplant with cells exposed to VPA+Li had significantly (P<.05) improved survival 
(12 of 14 mice survived) compared with control mice that received cells cultured with GFs 
only (6 of 14 mice survived; Figure 3A). In addition, blood cell counts showed that the red 
blood cell numbers and platelet numbers recovered faster in recipients of VPA+Li-treated cells 
compared with control mice, confirming more progenitor cell activity in the transplanted cell 
population (Figure 3B-C). In contrast, mice reconstituted with cells cultured in the presence 
of a single drug, either VPA or Li, did not show improved survival or blood recovery over mice 
that received a transplant with cells differentiated with GFs only (supplemental Figure 1). These 
data strongly indicate that the combination of VPA+Li most potently preserved immature, 
radioprotective hematopoietic progenitor cells.
To evaluate the effects of VPA+Li treatment on long-term repopulating capacity, the 
cultured progeny of 2000 LSK cells was transplanted into lethally irradiated recipients together 
with freshly isolated BM competitor cells. Recipient mice transplanted with cells cultured in the 
presence of VPA+Li displayed higher chimerism levels through the entire time course of the 
experiment compared with mice that received a transplant with cells cultured in the presence 
of GFs only. However, the differences between the 2 groups decreased over time (Figure 3D). 
The percentage of chimerism was significantly higher in the VPA+Li group up to 13 weeks after 


























Figure 2. Enhanced in vitro function of cells differentiated in the presence of Li and VPA. Cells 
differentiated in vitro with or without VPA and/or Li were assayed for progenitor/stem cell activity. (A) 
CFU-GM data showing effect of the compound treatment on the total number of colonies. Shown is the 
mean ± SD. (B) CAFC data showing progenitor (day-7) and stem cells (day-35) activity of 7-day cultured 




transplantation, suggesting robust preservation of short-term repopulating stem/progenitor 
cells. Furthermore, 28 weeks after transplantation only 2 of 5 recipients transplanted with cells 
cultured with GFs only reached chimerism levels > 1%, whereas > 1% of donor cell contribution 
was observed for all mice (5 of 5) in the VPA+Li group. Chimerism levels remained stable and 
distinguishable between the 2 groups until 36 weeks (supplemental Figure 1). In addition, 
treatment with VPA+Li did not influence the multilineage capacity of the cells because all mature 
blood types were found in comparable ratios (supplemental Figure 1). Collectively, these data 
strongly indicate that addition of VPA+Li to differentiation-inducting cultures preserved cells 
with in vivo repopulation potential.
Figure 3. Improved radioprotection and short-time engraftment on BM transplantation with cells 
exposed to VPA+Li. LSK cells cultured for 7 days with GM-CSF and SCF in the presence or absence of 
VPA+Li were transplanted into lethally irradiated recipients with or without competitors. (A) Survival of the 
recipients was screened for 40 days after noncompetitive transplantations. Significance was calculated 
with Mantel-Cox test (P = .043) and Gehan-Breslow-Wilcoxon test (P = .0394). (B) Platelet counts in the 
peripheral blood of recipient mice at 10 to up to 40 days after transplantation. Error bars represent SEM. (C) 
Red blood cell counts in the peripheral blood of recipient mice at 10 to up to 40 days after transplantation. 
Error bars represent SEM. (D) LSK cells cultured for 7 days were competitively transplanted with fresh BM 
cells into lethally irradiated recipients. Percentage of donor cells in the peripheral blood of recipient mice 
up to 28 weeks after transplantation. Error bars represent SEM (n = 5). The differences between groups 
were evaluated by Welch t test, *P <.05. 
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VPA increases proliferation and self-renewal of committed myeloid progenitors. Since our 
results indicate that VPA and Li enhanced short-term repopulating progenitor cells, the effects of the 
compound treatment on distinct progenitor cell subsets were characterized. To address this question 
we isolated by flow cytometry uncommitted (LSK) and committed myeloid (CMP and GMP) cell 
subsets and performed methylcellulose assays for each sorted cell population (Figure 4A). Cells were 
stimulated to differentiate with SCF and GM-CSF in the presence of VPA and/or Li. VPA and VPA+Li 
decreased colony-forming activity of LSK cells, showed no effect on clonogenic activity of CMP 
cells, but displayed strong potentiating effect on colony-forming ability of the GMP cell population 
(Figure 4A). GMPs had a limited colony-forming ability (~40 colonies per 1000 cells), which increased 
in the presence of VPA and VPA+Li by almost 8-fold. Li, as a single agent, showed no effect on colony-
forming ability of the tested progenitor cell populations.
To investigate whether the observed effects on clonogenic activity were caused by either 
proliferation or cell death (or both), single-cell proliferation assay was performed. Single cells 
of each distinct progenitor population (LSK, CMP, GMP) were sorted into 96-well plates in liquid 
differentiation medium containing SCF and GM-CSF and were cultured in the presence or absence 
of VPA and/or Li for 7 days. Cell death was not significantly affected by drug treatment in any of the 
tested cell populations (Welch t test, P>.05; Figure 4B). Cell proliferation was quantified by scoring 
the size of the clone grown from a single cell. Clone size was classified as small, medium, or large. 
Less than 40% of GMPs at the single-cell level were able to grow into medium or large colonies, 
whereas on addition of VPA and VPA+Li > 80% of colonies grow into larger (medium + large) 
colonies. The enhancing effect of VPA and VPA+Li on cell proliferation was also apparent at the 
level of CMPs, however, to a lesser extent. Surprisingly, VPA and VPA+Li decreased proliferative 
capacity of the LSK cells. At the single-cell level Li alone showed no effects on the proliferation 
of distinct hematopoietic cell populations (Figure 4B). These data indicate that VPA displayed a 
major effect on cell proliferation, which was potentiated in the presence of Li.
Next, the effect of VPA treatment on plating efficiency of distinct cell progenitor populations 
was tested with the use of single-cell CFU assay. Single cells of each of the 3 progenitor 
populations were sorted into 96-well plate in semisolid medium with SCF and GM-CSF and 
cultured with or without VPA and/or Li. VPA and VPA+Li decreased the plating efficiency of LSK 
cells, did not influence CMP plating efficiency, but significantly increased the plating efficiency 
of GMP at the single-cell level (in accordance with Figure 4A). Strikingly, whereas only 10% of 
purified GMPs were able to produce colonies in the presence of GFs only, the addition of VPA 
or VPA+Li increased clonogenic activity of GMPs to 60% (Figure 4C). Next, the self-renewal 
potential of compound-exposed cells was determined by replating colonies derived from a 
single cell. From each group, approximately 30 individual colonies were harvested and replated 
to new methylcellulose cultures in the presence or absence of VPA and/or Li. In the presence of 
GF only ~50% of individual colonies formed by single LSK cells were able to generate secondary 
colonies, whereas on exposure to VPA and VPA+Li 100% of the replated colonies derived 
from single LSK cells gave rise to secondary colonies. Furthermore, VPA and VPA+Li not only 
enhanced LSK replating efficiency of individual colonies but also increased the total number of 
secondary colonies derived from a single cell. Strikingly, although CMP and GMP cells did not 




activity of these progenitor populations, resulting in ~60% and ~35% of secondary colonies, 
respectively. The addition of Li to primary or secondary single-cell cultures did not affect cell 
(re)plating efficiencies (Figure 4D).
Summarizing, the effect of VPA or the combination of VPA+Li on colony-forming 


























































































































































































Figure 4. Increased proliferation and induction of replating activity of committed myeloid progenitors 
on VPA and VPA+Li treatment. Primary myeloid progenitor subpopulations were sorted by flow cytometry, 
and the effect of VPA+Li exposure on proliferation, colony-forming ability, and self-renewal potential was 
tested. (A) Influence of VPA and/or Li on CFU-GM activity of distinct myeloid subpopulations. Data are 
presented as colony forming cells per 10 000 cells. Shown is the mean ± SD. (B) Single-cell proliferation 
potential of distinct myeloid progenitor subpopulations in liquid culture with SCF and GM-CSF in the 
presence or absence of VPA and Li. After 7 days of culture, the number of wells with dead cells and the size of 
clones derived from single cells were scored. Clone size was classified as small (1-100 cells), medium (101-30 
000 cells), or large (30 000 to < 150 000; n = 192-288). Cell death, defined by the percentage of wells with 
dead cells, was not significantly different from control conditions (GFs only) on the compound treatment in 
any of the tested cell populations (Welch t test LSK+Li, P= .8; LSK+VPA = .13; LSK+Li + VPA, P=.13). (C) Effects 
of the adding compounds on single-cell colony-plating efficiency of distinct myeloid progenitors. Data are 
shown as the percentage of cells with colony-forming ability. (D) Ability of distinct myeloid progenitors 
to generate secondary CFU-GM colonies derived from a single cell (n = 20-48). The bars represent the 
percentage of single cell–derived primary colonies that gave rise to secondary CFU-GM colonies. The 
individual colors in the bars indicate the number of secondary CFU-GM colonies derived from the single 
cell. The differences between groups were evaluated by Welch t test, *P <.05, **P <.01, and ***P <.001.
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proliferation and colony-forming ability of LSK cells but increased its self-renewal potential 
measured by replating. Although proliferation and clonogenic activity of CMPs were not 
significantly influenced, VPA and VPA+Li induced replating capacity of this population. GMPs 
were specifically sensitive to VPA or the combination treatment, because the compounds 
not only strongly increased clonogenic activity, plating efficiency, and proliferation of this 
population but also induced their self-renewal capacity.
VPA and Li synergistically preserve HSPC gene expression profile. To identify molecular 
events by which VPA and/or Li are able to inhibit differentiation, we performed expression 
arrays on 7-day differentiated LSK cells in the presence or absence of VPA with or without 
Li. RNA samples were harvested at the time when in vitro and in vivo assays were initiated. 
Differential expression analyses (for details, see “Gene expression analysis”) showed distinct 
effects of Li and VPA on gene expression. Although no differentially expressed genes could 
be identified on Li treatment compared with GFs only (Figure 5A), VPA significantly affected 
60 genes, of which 10 were up-regulated and 50 down-regulated. Strikingly, an obvious more 
than additive effect was observed when Li was added to VPA in our differentiation cultures. 
The combined treatment of VPA+Li resulted in differential expression of 360 genes (110 up-
regulated and 250 down-regulated), showing a strong synergistic effect (Figure 5A). The lists 
of all genes differentially expressed on the compounds treatment is presented in supplemental 
Table 1. To assess whether VPA+Li treatment inhibited differentiation by preserving a primitive 
cell transcriptome, the changes in expression of VPA+Li targets (Figure 5A and supplemental 
Table 1) were compared with normal hematopoietic differentiation. For this purpose, previously 
obtained transcriptome data of 4 developmentally distinct hematopoietic cell stages, stem 
cells (Lin-Sca1+ckit+), progenitors (Lin-Sca1-ckit+), myeloid (Gr1+), and erythroid (Ter119+) cells, 
were used.29 Analysis found that target genes that were up-regulated by VPA+Li were more 
abundantly expressed in primary stem/progenitor cells compared with differentiated myeloid 
and erythroid cells, whereas VPA+Li down-regulated targets showed the opposite pattern, 
being higher expressed in differentiated than in uncommitted cells. (Figure 5B) Since VPA+Li 
treatment altered expression of 360 genes, an important question is whether expression 
changes of these targets are all independent or co-regulated. Cellular differentiation is 
most probably orchestrated by networks of co-regulated genes, rather than by changes in 
expression of individual genes. To address this question, the method described in detail by Voy 
et al30 was used. First, gene correlation studies (using Pearson coefficient) were performed with 
the same transcriptome data of the 4 developmentally distinct hematopoietic cell stages as 
used for determining cell type expression abundance of VPA+Li affected targets. The strongest 
correlations, most probably reflecting biologic relevance, were defined by less than -0.8 or > 
0.85 thresholds and visualized with Gephi Version 0.8 beta software.31 Such a gene relevance 
network, reflecting similarity measures of gene expressions in 4 cell populations, is presented 
in Figure 5C. VPA+Li targets were color-coded according to the expression abundance. 
Interestingly, it appeared that VPA+Li targets are co-regulated during normal hematopoietic 
differentiation, creating high connectivity networks. In addition, genes clustered together 
according to a specific cell type, creating a network consisting of 3 apparent clusters. One 
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Figure 5. Stem/progenitor cell gene expression profile synergistically preserved by VPA+Li. (A) Venn 
diagram representation of significantly differentially expressed genes on Li, VPA, or VPA+Li treatment. Venn 
diagram were created with Venny. (B) Rank-based heat maps of expression levels of genes up-regulated or 
down-regulated by VPA+Li in 4 freshly isolated cell types, stem (LSK), progenitor (L-S-K+), myeloid (Gr1+), 
and erythroid (Ter119+) cells. Heat maps were created with Genesis Version 1.7.6 software.50 (C) Graphic 
representation of gene networks affected by VPA+Li. For similarity measure, Pearson correlation was used 
with a threshold of > 0.85 (FDR P < .1).30 The network consists of nodes (genes) and edges (biologic relations 
between nodes). Size of nodes corresponds to amount of connection of a particular node with other nodes. 
Nodes are color-coded according to their expression abundance in 4 distinct cells types, green nodes 




progenitor (yellow) cells, and 2 separate clusters contained genes predominantly expressed in 
myeloid (blue) or erythroid (purple) cells (Figure 5C). Network analysis found also differential 
gene induction or repression by the treatment. As expected, genes within a cluster, usually 
expressed in the same cell type, showed positive correlations (red lines) with each other, 
suggesting that expression levels of these genes are changed in parallel by VPA+Li. However, 
strong negative correlations (blue lines) were apparent between genes belonging to separate 
clusters. Almost all genes within the stem/progenitor cluster displayed inverse correlation with 
genes within myeloid and erythroid clusters, indicating interesting gene relations between 
uncommitted and differentiated cells. Collectively, our analyses show that VPA+Li affected 
the differentiation program of the cell by perturbing the coordinated expression of multiple 
genes in co-regulated fashion, preserving stem/progenitor genes, and down-regulating 
differentiation-associated genes.
To try to identify primary candidates probably involved in cell fate decisions, the VPA+Li 
target list was filtered for transcription factors (TFs) and other DNA and RNA interacting genes. 
Table 1 provides a full list of transcriptional regulators that were affected by the treatment. A 
reduced network retained the 3-cluster structure with strong negative correlations between 
stem/progenitor and differentiated-cell associated TFs (Figure 5D). Among VPA+Li up-
regulated targets were several known stem/progenitor TFs, such as Gata2, Gfi-1, and HoxA7.33-35 
Other TFs, with still unknown functions in HSCs, could also be assigned to the stem cell cluster, 
including Rbbp7 and Phf5. Moreover, TFs involved in epigenetic events, such as Hmgn3 and 
Prmt5, were up-regulated by the VPA+Li treatment.36 In contrast, most of the down-regulated 
targets were correlated with cellular differentiation, including known TFs for myeloid (Erg1/2, 
Junb),37,38 erythroid/megakaryocyte (Dab2),39 and lymphoid (Irf5, Nfkbia)40,41 differentiation. TFs 
up-regulated by the treatment, showing a negative correlation with differentiation-associated 
TFs, seem to be especially interesting as targets for differentiation-preventing agents.
Because VPA is an epigenetic modifier, known to affect gene expression by preventing 
chromatin deacetylation, we tested whether the observed changes in gene expression were 
caused by altered histone acetylation levels. To this end, ChIP with the use of Abs against 
acetylated histone H4 were performed. As proof of principle, HoxA7, up-regulated by both 
VPA and VPA+Li, was selected for ChIP assay. Interestingly, several reports have suggested that 
another homeobox gene, HoxB4, is a target of VPA in human cells.16-18 In our study, expression 
of HoxB4 was not affected by the compound treatment. The ChIP experiments showed that 
VPA caused hyperacetylation of histone H4 at regulatory sites of the HoxA7 promotor, but 
not of the HoxB4 promotor. This correlates with the 2.3- and 8-fold higher HoxA7 expression 
measured by microarray and quantitative RT-PCR (not shown), respectively, and lack of change 
progenitors (L-S-K+), blue nodes are prevalent in mature myeloid cells (Gr1+), and purple nodes are expressed 
in mature erythroid cells (Ter119+). Lines represent correlations of particular genes with others, blue lines 
represent negative correlations, and red lines indicate positive correlations. Nodes with < 1 connection were 
removed. (D) TF networks significantly changed by VPA+Li treatment. This graph shows essentially the same 
data as those in panel C, but now only for transcriptional regulators. All network visual representation were 
performed with Gephi Version 0.8 beta software.31 (E) Acetylation status of histone H4 at promoter regions 
of HoxA7 and HoxB4 genes. β-actin was used as a housekeeping gene control for ChIP experiments.
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in HoxB4 expression. As expected, Li did not affect the epigenetic status of promotor regions 
of tested genes (Figure 5F). This indicates that VPA affected expression of HoxA7 by increasing 
histone acetylation on regulatory regions of the gene.
Taken together, genome-wide gene expression profiling of VPA- and Li-treated cells 
showed the synergistic effects of these 2 compounds at the molecular level. Gene relevance 
networks indicated that these effects required simultaneous changes in multiple genes to 
prevent differentiation, which was achieved by enhancing genes involved in cell primitiveness 
and repressing genes associated with cellular differentiation.
DISCUSSION
To date, attempts to define culture conditions that would favor stem cell self-renewal 
over differentiation have resulted in limited success. We hypothesized that combinations 
of cytokines and small molecules might represent an integrative approach to prevent 
differentiation in culture. In this report, we tested the combination of a well-known HDI, 
VPA, with the simple cation, Li, on HSPC maintenance under strong differentiation pressure 
and showed that the combination of these 2 compounds displayed strong anti-differentiation 
effects on hematopoietic differentiation at the biologic and the molecular levels. Although Li 
as a single agent displayed limited effects on HSPC differentiation, VPA and the combination 
of VPA+Li were able to preserve in vitro functionality of LSK and induced self-renewal of 
committed progenitors (CMPs and GMPs). Strikingly, after a 7-day differentiation culture only 
the combination of these 2 agents provided radioprotection to lethally irradiated recipients, 
shortened the time required for platelet and red blood cell recovery, and enhanced in vivo 
repopulation potential. These observations are consistent with previous reports, suggesting 
that VPA or Li, can affect fate decision of HSPCs,16-18,20-22,25,26 but to our knowledge this is the first 
report to show that VPA+Li act synergistically to delay HSPC differentiation.
In accordance with the biologic data, the most compelling evidence that VPA+Li act 
synergistically to inhibit LSK differentiation was provided by genome-wide gene expression 
analysis. Strikingly, VPA+Li affected expression of 360 genes, whereas VPA alone affected only 
60 genes, and Li did not affect any genes. Network analysis provided evidence that most genes 
affected by VPA+Li were co-regulated during normal hematopoietic differentiation. In addition, 
VPA+Li preserved expression of stem cell-related genes, which coincided with repression of 
genes involved in differentiation. This indicates that the anti-differentiation effects of VPA+Li 
are caused by coordinated changes in multiple co-regulated genes, rather than in individual 
genes. Our findings were further illustrated by the fact that TFs (probably being the primary 
targets in the network) favoring self-renewal (eg, Gata2, Gfi-1, HoxA7)33-35 were increased, and 
differentiation-associated TFs were decreased on VPA+Li treatment. It has been suggested that 
competition and balance between TFs, such as Gata2, PU.1, Gfi-1, Erg1/2, may regulate switches 
between self-renewal and differentiation and triggers the determination of cell fate.3,37,42-44 
The inhibition of the differentiation program was shown for multipotent uncommitted and 
also for committed cells, which are at various stages of differentiation. Strikingly, on addition 




in methylcellulose assays, suggesting possible cellular de-differentiation. However, whether 
the same mechanism is responsible for the effects of Li+VPA on committed progenitor 
differentiation versus LSK differentiation remains to be determined.
The balance between histone acetylation and deacetylation is thought to play an important 
role in maintaining chromatin structure consistent with the stem cell state. Epigenetic 
regulation is believed to be important for cell fate decision, and epigenetic transcriptional 
repression was suggested to be required for silencing of stem cell genes and subsequent cell 
differentiation.14,15,44 VPA has been shown to inhibit HDACs and therefore could interfere with 
the epigenetic status of the cell.8 We confirmed increased histone acetylation at the HoxA7 
promotor region, correlating with the increased expression of HoxA7. In addition, other 
confirmed VPA+Li targets (Gata2) have been suggested to bind to HDAC or to be involved 
in epigenetic modifications (Hmgn3, Prmt5).36,45 Moreover, the chromatin conformation 
maintained by VPA might allow a spectrum of Li targets to be better accessible. Thus, common 
targets of VPA and Li (eg, Wnt pathway)46 in combination with more accessible chromatin 
conformation may result in the observed synergistic effect of these 2 compounds. Therefore, 
modulation of epigenetic regulation of gene expression, as shown here with VPA, can lead to 
coordinated preservation or up-regulation of genes involved in stem cell maintenance and 
simultaneous down-regulation of differentiation-associated genes. The resemblance with 
expression patterns during natural differentiation suggests a physiologic mechanism driving 
expression of multiple genes determining cell fate. Self-renewal and differentiation seem to be 
strongly co-dependent, thus ex vivo stem cell culturing systems should target both processes 
to maintain uncommitted cells.
Methods to inhibit stem cell differentiation may be of benefit in ex vivo cell therapy 
protocols, which favor in vitro HSPC self-renewal rather than commitment and differentiation. 
So far, culturing systems with “classic” hematopoietic GFs resulted in stem cell loss because of 
profound differentiation.1,2 Recently, factors other than classic hematopoietic GFs (eg, RA, VPA, 
FGFs, SR1, pleiotropin)9,10,18,47,48 showed a promising potential in ex vivo expansion protocols. 
Our study underlines that combinatorial screening of Li and VPA and other new compounds 
may uncover possible additive and/or synergistic effects to modulate HSPC self-renewal and 
differentiation and thereby may lead to novel approaches in ex vivo stem cells culturing systems.
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Figure S1. Effects of VPA and/or Li treatment on radioprotection and long-time repopulation ability 
of BM cells. LSK cell cultured for 7 days with GM-CSF and SCF in the presence or absence of VPA and/
or Li were transplanted into lethally irradiated recipients with or without competitors. (A) Survival of 
the recipients was screened for 40 days following non-competitive transplantations. Significance was 
calculated using Mantel-Cox test (p=0.043) and Gehan-Breslow-Wilcoxon test (p=0.0394). (B) Platelet 
counts in the peripheral blood of recipient mice at 10 up to 40 days post-transplantation (Non-competitive 




Supplemental information available online on request
Table S1. Gene expression dataset on GFs, Li, VPA, and VPA+Li- treated cells.  
(http://bloodjournal.hematologylibrary.org/content/119/13/3050/suppl/DC1)
blood of recipient mice at 10 up to 40 days after transplantation (Non-competitive transplantations). 
Error bars represent standard error of the mean. (D) The blood cell type distribution presented as 
percentage of distinct mature cells type contribution into the donor blood cell population at 28 weeks 
post-transplantation (competitive transplantations). (E) Percentage of donor cells in the peripheral blood 
of individual recipient mice at 28 weeks post-transplantation (competitive transplantations, the same as 
on figure 4C). Error bars represent standard error of the mean (n=5). (F) Percentage of donor cells in the 
bone marrow of individual recipient mice at 36 weeks post-transplantation (competitive transplantations). 
Error bars represent standard error of the mean (n=5). (G) Percentage of donor cells in the LSK fraction of 
bone marrow of individual recipient mice at 36 weeks post-transplantation (competitive transplantations). 
Error bars represent standard error of the mean (n=5). The differences between groups were evaluated by 
Welch’s t test, *P<.05. 
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CHAPTER 5
ABSTRACT
Histone deacetylase inhibitors (HDIs) have been shown to enhance hematopoietic stem and 
progenitor cell activity and improve stem cell outcomes after ex vivo culture. Identification 
of gene targets of HDIs is required to understand the full potential of these compounds 
and can allow for improved stem cell culturing protocols. The molecular process that 
underlies the biological effects of valproic acid (VPA), a widely used HDI, on hematopoietic 
stem/progenitor cells was investigated by studying the early-response genes of VPA. 
These genes were linked to VPA-induced enhancement of cell function as measured by in 
vitro assays. Genome-wide gene expression studies revealed over-representation of genes 
involved in glutathione metabolism, receptor and signal transducer activity, and changes 
in the hematopoietic stem/progenitor cells surface profile after short, 24-hour VPA 
treatment. Sca-1, a well-known and widely used stem cell surface marker, was identified 
as a prominent VPA target. We showed that multiple HDIs induce Sca-1 expression on 
hematopoietic cells. VPA strongly preserved Sca-1 expression on Lin-Sca1+ckit+ cells, but 
also reactivated Sca-1 on committed progenitor cells that were Sca-1neg, thereby reverting 
them to the Lin-Sca1+ckit+ phenotype. We demonstrated that reacquired Sca-1 expression 
coincided with induced self-renewal capacity as measured by in vitro replating assays, 
while Sca-1 itself was not required for the biological effects of VPA as demonstrated using 
Sca-1-deficient progenitor cells. In conclusion, our results show that VPA modulates several 
genes involved in multiple signal transduction pathways, of which Sca-1 was shown to mark 





Hematopoietic stem cells (HSCs) are characterized by their self-renewal capacity and ability 
to generate all mature blood cells via a well-defined differentiation cascade. Hematopoietic 
lineage specification occurs in a stepwise process of commitment that eventually leads to 
formation of myeloid and lymphoid lineages.1,2 Although HSCs differentiate and progress down 
the hematopoietic hierarchy, their multipotency, self-renewal, and lineage choice become 
progressively and irreversibly restricted.3,4 However, identification of mixed lympho-myeloid 
progenitors suggests that some overlap between these two lineages does exist.5,6 Lineage 
restriction can be overcome to some extent by ectopic expression of key lineage-specific 
transcription factors, for example, overexpression of myeloid transcription factors PU.1 or 
CEBPα in differentiated lymphoid cells resulted in transdifferentiation of these cells into 
macrophages, whereas overexpression of GATA-1 caused switching from myeloid to erythroid 
lineage.7-9 Hematopoietic stem and progenitor cells can be identified by a specific cell surface 
marker profile, by the capacity of dye efflux, or on the basis of their metabolic properties.10 In 
combination with other markers, Sca-1 is the most commonly used cell surface marker to enrich 
for adult murine HSCs. The Ly-6a gene, more widely known as Sca-1, encodes for a glycosyl 
phosphatidylinositol-anchored cell surface protein of the Ly6 family and is one of the early 
markers expressed on emerging HSC.11 During adulthood, Sca-1 is present on both primitive 
and more differentiated cell subsets, suggesting complex regulation during hematopoietic 
ontology.12 Sca-1 expression phenotypically separates the stem cell compartment from 
committed myeloid progenitors, and its rapid down-regulation has been shown to be crucial 
for myeloid differentiation.13 Transplantations with purified cells and gene knock-in reporter 
studies have indisputably shown the utility of Sca-1 as an HSC marker.14-16 In addition, studies 
with Sca-1 knockout (KO) mice suggest that Sca-1 is not only a stem cell marker, but can also 
regulate the developmental program of HSCs and progenitor populations.13,17 Although there 
has been much speculation about the putative Sca-1 function and mechanism of its action, the 
role of this marker in HSCs remains enigmatic. Previously, we reported on the maintenance of 
Sca-1 (and c-kit) expression on hematopoietic stem/progenitor cells (HSPCs) and preservation 
of their functional potential after long-term in vitro treatment with valproic acid (VPA), a 
histone deacetylase inhibitor (HDI).18 Additionally, VPA has been shown to display an important 
biological effect on HSCs and their committed progeny.18-23 HDIs can affect gene expression 
by preventing histone deacetylation and modifying the chromatin structure at regulatory loci 
of the gene. Importantly, HDIs including VPA have been used in leukemia as a differentiation 
therapy. Therefore, it is crucial to understand the full spectrum of HDI-related effects. The 
molecular process that underlies the biological effects of HDIs can be illuminated by detecting 
HDI-responsive genes. In a previous report, we determined molecular consequences of 
long-term VPA treatment and we showed that this HDI preserved HSPC function and gene 
expression profile after a 7-day culture. Here, we performed microarrays after short-term, 
24-hour VPA stimulation to identify early-response VPA targets in HSPCs. Our data provide 
the first analysis of direct VPA targets in primitive hematopoietic cells and show that Sca-1 is a 
faithful marker to identify HDI-responsive cells after in vitro culture.




Mice. Female wild-type C57BL/6 mice (Harlan, Horst, The Netherlands) or Sca-1-deficient 
C57BL/6 mice (Sca-1 KO mice) were used as a source of hematopoietic cells. Sca-1 KO mice 
were originally generated by William Stanford, University of Toronto, Canada and were kindly 
provided to us by Marieke Essers and Andreas Trumpp, Heidelberg Institute for Stem Cell 
Technologies and Experimental Medicine (Heidelberg, Germany). The local animal ethical 
committee of the University of Groningen approved all animal experiments.
Isolation of hematopoietic cell populations. Mice were anesthetized and sacrificed by cervical 
dislocation. Unfractionated bone marrow cells were obtained by crushing femora, tibiae, and pelvic 
bones. Cell suspensions were filtered through a 100-µm cell strainer (BD Biosciences) to remove 
debris and the cells were counted on a Medonic CA620 analyzer (A.Menarini Diagnostics). After 
erythrocyte lysis, cells were stained with lineage cocktail (i.e., A700-Mac1, A700-Gr1, A700-Ter119, 
A700-CD3, and A700-B220), Pacific Blue-Sca1, phycoerythrin (PE)-ckit, fluorescein isothiocyanate 
(FITC)-CD34, and PE-Cy7-CD16/32 for isolation of uncommitted and committed cells. For isolation 
of differentiated cell populations, cells were stained with selected lineage markers, FITC-Ter119, 
PE-Gr-1, allophycocyanin-(APC)-CD115, PE-Cy7-CD169, and Pacific Blue-Sca-1. Subsequently, cells 
were resuspended in propidium iodide solution (1 mg/mL) and uncommitted (Lin–Sca1+ckit+ 
[LSK]), committed (common myeloid progenitors [CMP]: L-SnegK+CD34highCD16/32mid, granulocyte-
macrophage progenitors [GMP]: L-SnegK+CD34highCD16/32high, and megakaryocyte-erythroid 
progenitors [MEP]: L-SnegK+CD34negCD16/32neg), and differentiated hematopoietic cell subpopulations 
(granulocytes: Ter119negB220negCD3negGr1high CD115negCD169neg, monocytes: Ter119negB220neg
CD3negGr1highCD115highCD169neg, macrophages: Ter119negB220negCD3negGr1mid/negCD115mid/negCD169mid/high, 
and erythrocytes: B220negCD3negGr1negTer119high) were sorted by a MoFlo XDP cell sorter or MoFlo 
Astrios (Beckman Coulter).24-26
Compounds and HDI stimulation. Fluorescence-activated cell-sorted (FACS) uncommitted, 
committed, and differentiated hematopoietic cell subpopulations were stimulated for 24 
hours with a range of HDI concentrations in the presence of 10% fetal calf serum, murine 
stem cell factor (300 ng/mL; Peprotech), and recombinant murine interleukin-11 (20 ng/mL; 
R&D Systems). Cells were cultured in StemSpan medium (StemCell Technologies) at 37°C in 
a humidified atmosphere and 5% CO
2
 in air. VPA (Sigma-Aldrich) was dissolved in phosphate-
buffered saline solution (PAA Laboratories GmbH), whereas MS-275 (Selleck) and Apicidin (Enzo 
Life Sciences) were dissolved in dimethyl-sulfoxide and further diluted in phosphate-buffered 
saline with 0.2% bovine serum albumin (to obtain the desired compound concentration). In 
case of two latter compounds, control cells were dimethyl-sulfoxide vehicle-treated with 
adequate dimethyl-sulfoxide concentration.
Gene expression analysis. Gene expression analysis was performed in LSK cells that 
were cultured for 24 hours in the presence or absence of VPA. All samples were analyzed in 
independent biological triplicates. Total RNA was isolated using the RNeasy kit (Qiagen), 
according to manufacturer’s protocol. RNA concentration, quality, and integrity were measured 




the Illumina TotalPrep RNA Amplification Kit (Ambion/Applied Bioscience) and hybridized to 
Mouse Ref-8_V2 expression platform (Illumina) according to the manufacturer’s instruction. 
Scanning was carried out on the iScan System (Illumina). Image analyses and extraction 
of raw expression data were performed using BeadStudio software (Illumina) with default 
settings, no background subtraction, and no normalization. Raw data were thresholded at 1, 
log2-transformed, and quantile normalized using GeneSpring-GX11.0 (Agilent). From the initial 
probe list (25,697 probes) probes not expressed in any replicate of the two conditions were 
excluded. The redefined list (16,050 probes) consisted of only those probes that were flagged 
as marginal or present. Default detection p value cut-offs of 0.8 for present and 0.6 for absent 
were used for flags. Probes significantly differentially expressed between VPA-stimulated and 
control cells were defined based on the three sigma rule.27,28 First, the mean (standard deviation) 
of both groups was defined, and second, genes for which the expression difference exceeded 
3 standard deviations were selected. For data with normal distribution, this approximately 
represents p<0.05. Subsequently, we applied >1.5-fold cutoff to select biologically relevant probes 
for differential expression. Finally, a redefined probe list was subjected to overrepresentation 
analyses using a gene set property analysis tool, Gene Trail.29 Analyses were performed with the 
Gene Trail default setting and a manually defined background consisting of all probes present on 
the murine Illumina Ref_8 arrays used in this study. All raw data were deposited in the NCBI Gene 
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/), accession number GSE41020.
Sca-1 induction. After 24 hours incubation in the presence or absence of an HDI, distinct 
cell populations were stained with a cocktail of antibodies as described and analyzed for 
Sca-1 marker expression by flow cytometry on the LSR-II flow cytometer (BD Bioscience). 
Alternatively, 24-hour incubated cells were harvested for Sca-1 gene expression analyses. 
Total RNA was isolated as described, followed by complementary DNA synthesis according 
to manufacturer’s protocol. The coding regions of Sca-1 gene were amplified by quantitative 
polymerase chain reaction (Bio-Rad) using gene-specific primer pairs for Sca-1 (fwd: 
TGGGTACTAAGGTCAACGTGAAGACTTCC rev: TGGAGGTCATTGGGAGGACCATCAG) and Gapdh 
(fwd: ATGGCCTTCCGTGTTCCTAC rev: GCCTGCTTCACCACCTTCTT).
Functional cell analysis. After 24 hours stimulation with or without VPA, cells were resorted based 
on Sca-1 expression by a MoFlo XDP cell sorter. Clonogenic potential of Sca-1neg and Sca-1pos cells 
from HDI stimulated and non-stimulated cultures of wild-type or Sca-1 KO cells was determined 
by colony-forming unit (CFU) assay. CFU assays were performed as described previously.18,30
Statistics. BeadStudio and GeneSpring GX 11.5 software were used for analysis of Illumina arrays. 
Data were further analyzed based on the three sigma rule and Gene Trail software as described. 
Differences in functionality of cell populations were analyzed using the Mann-Whitney U test 
(IBM SPSS software, Armonk).
RESULTS
Identification of early VPA-responsive genes. Previously, we demonstrated enhancement 
of HSPCs function and induction of self-renewal capacity of committed progenitors after 
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7-day VPA treatment and identified molecular changes induced by a 7-day VPA treatment 
of HSPCs.18 However, 7-day stimulation of cells with VPA will lead to a cascade of molecular 
events that will preclude identification of early VPA targets. To overcome this and to identify 
early VPA-responsive genes in HSPCs, we analyzed gene expression profiles of LSK cells 
as early as 24 hours after onset of incubation with or without VPA (Figure 1A). We identified 
366 differentially expressed probes (Supplementary Table S1) representing 1.4% of all probes 
present on the array. The low number of VPA-affected genes is in agreement with previously 
reported effects of HDIs, suggesting that these compounds affect only a small fraction of the 
genome.31-33 Among the differentially expressed probes, 298 probes were up-regulated and 68 
probes were down-regulated upon 24 hours VPA stimulation. Because HDIs are expected to 
prevent deacetylation of histones, we focused on up-regulated genes as primary VPA targets. 
Among those, transcriptional regulators and genes involved in chromatin remodeling were 
found, such as Egr1, Rb1, Tshz3, Bahd1, or Hmgn3. Of these, Egr1 has been implicated in HSC 
functioning34, but the other genes can also play a role in HSC. To functionally assign the VPA 
affected genes and to test whether any category of genes was over-represented in the set, 
we subjected the list of 298 up-regulated probes to over-representation analyses according to 
Gene Ontology categories using Gene Trail. Target genes could be categorized into two main 
cellular compartments: intracellular/cytoplasmic compartment and membrane compartment. 
Among the over-represented categories were glutathione metabolism, cell communication, 
signal transducer activity, and receptor activity (Figure 1B). Glutathione metabolism can 
be considered as an early cellular response to VPA and mechanism of its detoxification.35,36 
However, we focused on the effects of VPA on the expression of signal transducers and 
receptors to identify markers on HSPC to detect HDI responsiveness. Over-representation of 
these categories is clearly prominent because half of the top 12 up-regulated early-response 
VPA targets (Figure 1C) included genes involved in signal activation and transduction. Among 
these genes were two widely known and used HSPC markers, Ly-6a (Sca-1) and Thy-1. Sca-1 is 
included in many hematopoietic staining protocols and is a solid stem cell marker for other 
adult stem cells as well. We further analyzed Sca-1 as a potential early response VPA target.
VPA (re-)induces Sca-1 expression at various levels of hematopoietic differentiation. To 
study the effects of VPA on Sca-1 expression during hematopoiesis in more detail, we isolated 
hematopoietic cells at distinct levels of differentiation. Undifferentiated LSK cells, committed 
progenitors that are negative for Sca-1 expression (CMPs, GMPs, and MEPs), and Sca-1neg 
differentiated cells (granulocytes, monocytes, macrophages, and erythrocytes) were incubated 
for 24 hours with or without VPA. After VPA stimulation, we reanalyzed Sca-1 marker expression 
on these cells by flow cytometry (Figure 2A). Of note, the concentration used in these 
experiments did not significantly affect cell numbers during the 24-hour incubation time (data 
not shown). During 24 hours culture, approximately 23% of purified LSK cells lost Sca-1 marker 
expression, whereas exposure to VPA strongly prevented this loss, resulting in 98% of cells with 
preserved Sca-1 expression and maintaining an immature LSK phenotype (Figure 2B). Next, we 
tested whether Sca-1 could be reactivated in CMPs and GMPs that had lost its expression during 
differentiation. After 24 hours incubation without VPA, a small percentage of CMP and GMP cells 




more than 30% of CMP and GMP cells reacquired Sca-1 expression, phenotypically reverting 
these cells to an LSK phenotype (Figure 2B). Furthermore, Sca-1 could also be reinduced on more 
differentiated cells, such as subsets of differentiated myeloid cells (FACS-sorted within Sca-1neg 
gate), including monocytes and macrophages, but not on granulocytes (Figure 2C). No difference 
in Sca-1 expression could be observed between VPA-stimulated and non-VPA-stimulated 
erythroid progenitors (MEP) or differentiated erythrocytes (Figure 2B, C). Additionally, Thy-1 
marker expression, the other HSPC marker identified as early VPA target, could also be induced 
on HSPCs after 24 hours stimulation with VPA, but to a lesser extent (data not shown). Together 
these data confirm the microarray results and show that VPA affects expression of known HSPC 
markers. Collectively, VPA can not only up-regulate Sca-1 expression on HSPCs that do express 
this marker, but also can reactivate Sca-1 on cells that have lost its expression in the process of 
differentiation, reverting CMP and GMP cells to a more immature LSK phenotype. In addition, 
myeloid cells are particularly sensitive to VPA-induced up-regulation of Sca-1.
Distinct HDIs (re-)induce Sca-1 expression in a dose-related manner. We tested whether 
the effects of VPA on Sca-1 expression were specific for VPA or were shared by distinct HDIs. To 
address this question, we selected two additional HDIs, Apicidin and MS-275, which differ from 
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Figure 1. Identification of early VPA targets. (A) Experimental design to test effects of 24 hours VPA 
treatment of LSK cells on gene expression. (B) Functional characterization of genes up-regulated by 24 
hours VPA stimulation. List of 298 probes representing 244 genes was subjected to over-representation 
analyses using GeneTrail according to GeneOntology (GO) categories. Genes assigned to common GO 
categories were grouped together (Supplementary Table S2; online only). The pie chart represents the 
significantly over-represented categories. (C) Table showing top 12 up-regulated genes after 24 hours VPA 
stimulation of LSK cells.
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reported to inhibit activity of both class I and class II histone deacetylase (HDACs). Apicidin, a 
cyclic tetrapeptide, and MS-275, a benzamide, are HDAC class I-specific inhibitors, with Apicidin 
being selective for HDAC-2 and -3 and MS-275 showing high selectivity toward HDAC-1 and 
-3.37 To assess the effects of these HDIs on Sca-1 expression, we FACS-sorted hematopoietic 
progenitors defined by the L-SnegK+ phenotype and reanalyzed Sca-1 expression on protein and 
messenger RNA levels after 24 hours stimulation with increasing HDI concentrations (Figure 
3A). All three tested HDIs, VPA, Apicidin, and MS- 275, (re-)induced Sca-1 expression on Sca-1neg 
hematopoietic cells in a concentration-dependent manner, on both protein and messenger 
RNA levels (Fig. 3B-D). VPA and Apicidin showed similar efficiency to induce Sca-1, resulting 
in 50% and 40% cells with induced Sca-1, respectively (Figure 3B, C). MS-275, highly selective 
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Figure 2. Effects of VPA on Sca-1 expression during hematopoiesis. (A) Experimental design to test the 
effects of VPA on Sca-1 expression during hematopoietic differentiation. (B) Representative FACS plots 
demonstrating the effects of 24 hours of VPA stimulation on uncommitted (LSK) and committed (CMP, GMP, 
MEP) hematopoietic cell populations. Cells on the graph were pre-gated for viable cell population based 
on SSC, FSC, and propidium iodide (PI) profile. (C) Representative FACS plots demonstrating the effects 
of 24 hours VPA stimulation on differentiated hematopoietic cell populations (monocytes, macrophages, 
granulocytes, and erythrocytes). Cells on the graph were pre-gated for viable cell population based on 
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Figure 3. Concentration-dependent Sca-1 induction by distinct HDIs. (A) Experimental design to 
test effects on distinct HDIs on Sca-1 protein and messenger RNA expression. (B) Short-term (24 hours) 
effects of increasing concentrations of VPA on Sca-1 expression. (C) Short-term (24 hours) effects of 
increasing concentrations of Apicidin on Sca-1 expression. (D) Short-term (24 hours) effects of increasing 
concentrations of MS-275 on Sca-1 expression.
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cells (Figure 3D). Additionally, the induction of Sca-1 expression was dependent on continuous 
presence of HDI because 24 hours after drug removal, 50% of (re-)induced Sca-1pos cells lost 
the marker expression (Supplementary Figure S1). Our data demonstrate that Sca-1 gene 
expression can be easily, quickly, and efficiently re-induced on Sca-1neg cells, and that the level 
of Sca-1 expression can be titrated by varying the HDI concentration.
Sca-1 re-induction correlates with enhanced in vitro cell clonogenic activity. Because 
expression of Sca-1 is of unknown functional relevance, we studied the biological consequences 
of Sca-1 (re-)induction. Previously, it was shown that VPA treatment can induce self-renewal 
activity of committed myeloid progenitors, CMPs and GMPs, as measured by methylcellulose 
replating activity.18 To test the functionality of cells that regained Sca-1 expression, we used 
the previously described CFU–granulocyte-macrophage assay setup. Committed myeloid 
progenitors (CMPs and GMPS) and more differentiated cells, defined by Lin+Sca-1neg phenotype, 
were FACS-sorted and incubated for 24 hours with or without VPA. After incubation cells were 
re-sorted and Sca-1neg and Sca-1pos cells were plated into CFU assays (Figure 4A). Because Sca-1 
expression and clonogenic activity of hematopoietic cells were shown to be HDI dependent 
(Supplementary Figure S1), VPA was present during the entire culturing period in case of 
re-sorted Sca-1neg as well as Sca-1pos cells. Primary colony counts showed enhanced CFU activity 
of cells that reacquired Sca-1 expression and that were derived from VPA-stimulated CMP 
as well as VPA-stimulated and non-stimulated Lin+Sca-1neg cells. However, no differences in 
primary CFU activity between Sca-1neg and Sca-1pos cells could be observed for non-stimulated 
CMP and both non- and VPA-stimulated GMP (Figure 4B). Strikingly, the self-renewal potential 
of Sca-1pos and Sca-1neg cell populations as tested by colony replating showed that for all tested 
cell populations (CMP, GMP, and Lin+Sca-1neg), both VPA-stimulated and non-stimulated, 
the majority of replating activity was derived from cells with reacquired Sca-1 expression. In 
addition, VPA-stimulated cells that regained Sca-1 expression showed much higher replating 
potential compared with non-stimulated Sca-1pos cells (Figure 4C). In addition, a higher number 
of VPA-stimulated cells regained Sca-1 expression compared with non-VPA-stimulated cells. 
These data indicate that VPA-enhanced replating capacity of CMP, GMP, and Lin+Sca-1neg cells 
and more than 90% of the replating capacity resided in cells with regained Sca-1 expression.
Sca-1 is dispensable for VPA-induced enhanced activity of hematopoietic cells. Because 
our results demonstrate that hematopoietic cells with re-induced Sca-1 expression display 
enhanced functional activity, we assessed whether Sca-1 is required for the observed effect. 
To test this, we performed CFU-granulocyte-macrophage assays using cells derived from Sca-
1-deficient mice (referred to as Sca-1 KO mice). Committed myeloid cell populations (CMP and 
GMP) and differentiated cells defined by Lin+ phenotype were FACS-sorted from wild-type and 
Sca-1 KO mice without Sca-1 marker selection. In this way, CMP, GMP, and Lin+ cells still contained 
approximately 10%, 2%, and 1% of Sca-1pos cells (determined in wild-type cells (Supplementary 
Figure S2). Minor differences with data presented on wild-type cells in Figure 4 were observed 
because cells were not selected on Sca-1 expression at 24 hours and sorting strategies were 
slightly different. Figure 5A shows that VPA effects on both primary and secondary clonogenic 
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Figure 4. Clonogenic activity of cells with reacquired Sca-1 expression. (A) Experimental design to test 
functional consequences of reacquired Sca-1 expression on hematopoietic cells that were negative for 
Sca-1. (B) Primary CFU-granulocyte-macrophage activity of Sca-1neg and Sca-1pos cells derived from VPA-
stimulated and VPA-non-stimulated CMP, GMP, or Lin+Sca-1neg cells after 24 hours culture. (C) Clonogenic 
replating potential of Sca-1neg and Sca-1pos cells derived from VPA-stimulated and VPA-non-stimulated CMP, 
GMP, or Lin+Sca-1neg cells after 24 hours culture. The replating activity of non-VPA-stimulated GMP could 
not be determined due to low cell numbers in Sca-1pos samples (only 0.6% of GMP induce Sca-1 without 
VPA stimulation) and therefore too low colony numbers. The difference between groups was evaluated by 
Mann-Whitney test using SPSS software; *p <0.05; ND = not determined.
VPA equally enhanced CFU–granulocyte-macrophage capacity of Lin+ population of both 
wild-type and Sca-1 KO cells (Figure 5B). In replating assays, all tested cell populations, from 
both wild-type and Sca-1 KO mice, showed strongly enhanced self-renewal potential upon VPA 
exposure (Figure 5C). To exclude the possibility that more primitive cells (Sca-1pos) contribute 
to the enhanced CFU activity, these results were confirmed in CMP and GMP cell populations 
that were strongly depleted of Sca-1pos cells (less than 1% Sca-1pos cells) using the SLAM marker 
profile (CD48+ and CD150+) (Supplementary Figure S2). These data clearly demonstrate that 
the Sca-1 molecule is dispensable for HDI-stimulated enhancement of cell functionality and 
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replating capacity. Although Sca-1 is not required for the biological effects of VPA, it marks 
only those cell populations with improved stem/progenitor cell readout upon VPA stimulation.
DISSCUSSION 
During the last several years, it has been shown that HDIs, particularly VPA, can retain HSPC 
activity during ex vivo culture.18-22 However, the molecular events of these effects are largely 
unknown. In this study, we set out to determine the early molecular response of HSPCs to 
VPA stimulation. Our genome-wide gene expression studies revealed over-representation of 
Figure 5. VPA effects on clonogenic activity of Sca-1-deficient hematopoietic cells. (A) Experimental 
design to test requirement of Sca-1 marker in the VPA-enhanced stem/progenitor cell activity. (B) Primary 
CFU-GM activity upon VPA stimulation of wild-type and Sca-1 KO-derived CMP, GMP, and Lin+ cells. 
(C) Clonogenic replating potential upon VPA stimulation of wild-type and Sca-1 KO-derived CMP, GMP, and 




genes with receptor and signal transducer activity and changes in the HSPC surface profile 
after short (24 hours) VPA treatment. We identified the well-known and widely used HSPC 
markers Sca-1 and Thy-1 as early VPA targets, and we found that distinct HDIs can readily and 
effectively induce expression of these markers on HSPCs. Particularly, Sca-1 is included in many 
murine HSC-sorting strategies, separating the stem cell compartment from a more committed 
myeloid compartment. Strikingly, after 24 hours culture, VPA not only strongly preserved Sca-1 
expression and the LSK phenotype of isolated HSPCs, but it also re-induced Sca-1 on committed 
progenitors (CMPs and GMPs) that had lost its expression in the process of differentiation, 
reverting those cells to a more immature LSK phenotype. The reacquired Sca-1 expression was 
accompanied by increased functional potential, as demonstrated by enhanced self-renewal 
activity in replating assays compared with Sca-1neg cells. Although Sca-1 was dispensable for 
observed HDI effects, it serves as a marker of VPA-responsive cells. 
HDIs, including VPA, are widely used in anti-cancer therapy, where they lead to cancer 
cell death. The VPA concentrations used in leukemia treatment seem to have no effect on 
non-transformed cells, making HDIs well suited for cancer therapy. However, recent studies 
indicate that VPA displays similar stem cell-enhancing effects on leukemia initiating cells38,39, 
suggesting that normal and transformed stem cells can respond uniformly to VPA stimulation 
and share the same targets. These findings emphasize the importance of understanding the 
spectrum of both biological and molecular effects of VPA. Our microarray data indicate that, 
in addition to cell communication and signal/receptor activity, HSPCs respond to VPA also by 
up-regulation of genes involved in glutathione metabolism. Because glutathione is involved 
in detoxification and anti-oxidation mechanisms, it can play a role in the selectiveness of anti-
cancer drugs, such as HDIs, toward transformed cells.40,41 Additionally, upregulation of genes 
involved in chromatin remodeling events, such as Hmgn3, Tshz3, or Prkcb1, were also observed 
after VPA stimulation, indicating effects on epigenetic mechanisms. The ability of all tested 
HDIs (VPA, MS-275, and Apicidin) to induce Sca-1 strongly suggest that regulation of Sca-1 
gene expression is epigenetically controlled and is due to specific HDI deacetylation inhibitory 
activity and not off-target effects of VPA. Additionally, because both Apicidin and MS-275 
(HDAC class I inhibitors) could effectively induce Sca-1, these suggest that neither inhibition 
of class II HDACs nor HDAC-1 or -2 seem to be crucial for regulation of Sca-1 gene expression. 
VPA treatment could therefore affect cell functionality by modulating chromatin conformation 
at key regulatory genes, which is considered to be important in determining the fate of HSCs. 
This study shows that VPA treatment can induce an LSK-like phenotype in committed myeloid 
progenitors by reactivating Sca-1. The committed cells reacquired replating activity, suggesting 
partial de-differentiation. Interestingly, addition of VPA to culture conditions used to reprogram 
differentiated cells into induced pluripotent stem cells has been shown to strongly improve the 
efficiency of induced pluripotent stem cell production.41 The acquisition of stem cell properties 
is accompanied by epigenetic variations, including genome-wide chromatin decondensation.42 
In addition, accessible chromatin is a general feature of stem cells.3,43 We postulate that VPA, by 
inhibiting deacetylation events, leads to hyperacetylation and confers a more open chromatin 
conformation to target cells, which can facilitate the de-differentiation process. Together, these 
data indicate that HDIs, such as VPA, might play a role in cellular reprogramming. It is likely that 
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for full reprogramming, additional factors are needed, such as key (HSC) transcription factors, 
because naturally occurring HSPC de-differentiation has not been reported. 
In combination with other markers, Sca-1 is the most commonly used marker to enrich for 
adult murine HSCs and also other adult stem cell types. In addition, Sca-1 is up-regulated in a 
variety of mammary tumors, likely reflecting cancer stem cell population, and suggesting its 
role in cell stemness.44,45 HSCs deficient for Sca-1 displayed a competitive disadvantage upon 
serial transplantations, suggesting HSC self-renewal defects.13,17 In addition, Sca-1 overexpression 
abrogated myeloid colony formation of mouse and human hematopoietic precursors, suggesting 
a role for Sca-1 in lineage specification.13 Sca-1 has also been suggested to play a role in activation of 
dormant primitive HSC by interferon-α.46 Multiple attempts have been made to identify a function 
of Sca-1, but no consensus has been reached and its role in stem cells has yet to be elucidated. 
Based on its high similarity with other Ly6 superfamily members, Sca-1 was hypothesized to 
act via receptor-ligand interactions and/or via modification of lipid rafts and subsequently cell 
signaling.12;48 However, to date, ligands for Sca-1 have not been found, suggesting that it might 
not function via classical receptor-ligand binging, but alternatively as a co-regulator of signaling 
pathways. Here, we report on over-representation of genes implicated in receptor and signal 
transducer activity, suggesting that VPA-induced Sca-1 expression might influence cell signaling 
as a coregulator of signaling pathways, for instance, by modulating lipid rafts composition.12,47 
Collectively, our data demonstrate that VPA can induce important effects on hematopoietic 
stem and progenitor cell self-renewal and differentiation. It was shown that Sca-1 is an early VPA 
target and that its expression is efficiently induced by VPA. Finally, we show that Sca-1 can serve 
as a marker of HDI-responsive cells, reflecting enhanced cell functionality. 
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Supplementary Figure S1. Dependence of Sca-1 expression and clonogenic activity on continuous 
presence of HDI. (A) Experimental design to test dependence of Sca-1 expression on the presence of VPA. 
(B) Sca-1 expression re-analyses of VPA treated and untreated cells. Cells were pre-gated based on SSC, FSC 
and propidium ionide for cell viability. (C) Experimental design to test dependence of clonogenic activity on 
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Supplementary Figure S2. Sca-1 expression and clonogenic activity of cells tested for increased 
functionality in WT and Sca-1 deficient hematopoietic cells. (A) Experimental design to test requirement 
of Sca-1 marker in the VPA-enhanced stem/progenitor cell activity. (B) Sorting strategies of hematopoietic 
populations from WT and Sca-1 deficient mice and Sca-1 percentages within sorted cell populations. In Lin+ 
cells only 4% of cells express Sca-1 in WT cells. Among Lin+CD150+CD48+ cells less than 2% of cells express 
Sca-1. (C) Cells sorted as CMP and GMP were pre-gated based on SSC, FSC and propidium ionide for cell 
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10% and less than 1% Sca-1pos cells, respectively. Within Lin-c-kit+CD150+ CD48+ cells less than 1% of cells 
express Sca-1. (D) Primary CFU-GM activity upon VPA stimulation of wild type and Sca-1 KO derived CMP 
(Lin-c-kit+CD150+CD48+CD16/32midCD34+), GMP (Lin-c-kit+CD150+CD48+CD16/32high) and Lin+CD150+CD48+ 
cells where Sca-1 expression was ignored but CD150 and CD48 were included as progenitor cell markers. (E) 
Clonogenic re-plating potential upon VPA stimulation of wild type and Sca-1 KO derived CMP, GMP and Lin+ 
cells where Sca-1 expression was ignored but CD150 and CD48 were included as progenitor cell markers.
Supplemental information available online on request
Table S1. Gene expression dataset on 24h cultured cells with or without VPA. 
Table S2. Gene Ontology classification of identified VPA-early response targets in hematopoietic cells.





SUMMARIZING DISSCUSION & FUTURE PERSPECTIVES

SUMMARy
Expansion of fully functional self-renewing, multipotent and engraftable HSCs is expected 
to be highly beneficial for stem cell-based therapies and represent a long-standing goal of 
stem cell biology. Despite intensive studies, defining the in vitro culture conditions that can 
maintain HSC characteristic properties of self-renewal and lack of differentiation has proven to 
be difficult. Therefore there has been much interest in understanding molecular (intrinsic) and 
environmental (extrinsic) determinants governing HSC fate decisions, as well as manipulation 
of HSC culture conditions to efficiently expand HSCs ex vivo. In this thesis we studied the 
biological and molecular effects of distinct, both intrinsic and extrinsic factors on HSC 
characteristics, particularly on stem cell maintenance, expansion and differentiation.
Chapter 2 provides an introduction to the concept and goals of HSCs expansion studies. 
We reviewed here past and recent HSC expansion approaches, briefly summarizing molecular 
factors playing a role in HSC fate decisions, further focusing on environmental cues, such 
as cytokines, developmental factors and small molecules, to regulate HSC self-renewal and 
differentiation in culture. We concluded that the most comprehensive approach to develop 
optimal HSC expansion conditions may involve a combination of currently studied methods. 
It is likely that these conditions would involve multiple biological and chemical compounds, 
which act in concert to induce cell survival and division while simultaneously preventing stem 
cell differentiation. Finally, we discussed in this chapter the remaining challenges of the field 
that need to be answered before unlimited ex vivo HSC expansion could be achieved.
One of these remaining challenges that could substantially contribute to the success of 
ex vivo HSCs expansion protocols is a better understanding of the molecular mechanisms 
regulating HSC self-renewal and differentiation. Several approaches can be used to identify 
intrinsic factors that play a role in HSC fate determination, such as identification of key stem cell 
specific genetic factors and/or studying the cues underlying known mouse-strain dependent 
variation in HSC frequencies. By applying these approaches in chapter 3 we determined 
whether changes and variation in microRNA expression could influence HSC fate. We performed 
genome-wide microRNA expression profiling of four developmentally related hematopoietic 
cell types isolated from the C57BL/6 (B6) and DBA/2 (D2) mice, and we determined the 
expression dynamics of microRNAs during hematopoietic differentiation. We focused on those 
microRNAs which expressions were both, down-regulated during stem cell differentiation 
and that were higher expressed in D2 cells compared to B6 cells, and thus correlated with 
HSPC frequency. This led to the identification of an evolutionary conserved microRNA cluster 
consisting of miR-99b, let-7e and miR-125a. A single member of this miR-cluster, miR-125a was 
identified to be responsible for the majority of the miR-cluster 99b/let-7e/125a overexpression 
phenotypes. Overexpression of this miR-cluster, or only miR-125a, in HSPCs increased the in 
vitro stem cell functionality measured by replating and CAFC assays, and conferred apparent 
competitive advantage in transplantation settings. However, detailed analysis of stem cell 
compartment revealed that HSCs overexpressing miR-cluster 99b/let-7e/125a were significantly 
compromised, resulting in stem cell exhaustion. Moreover, we found that mice reconstituted 
with cells overexpressing the miR-cluster exhibited increased myeloid differentiation, leading to 
development of myeloproliferative neoplasm that occasionally progressed to leukemia. Finally, 
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we identified candidate functional targets through which miR-125a could modulate HSPC fate. 
Results discussed in this chapter clearly show that microRNAs could influence HSC self-renewal 
and differentiation properties. However, overexpression of miR-125a, identified as a stem cell 
specific microRNA, after an initial boost of myeloid output cells, negatively influenced primitive 
HSC numbers, and subsequently exerted a disease phenotype. Therefore, miR-125a does not 
qualify as a potential candidate for HSCs expansion protocols.
Introduction of genetic material is undesired in clinical HSC expansion protocols as it might 
result in undesired clinical outcomes. Alternatively, the HSC stemness could be stimulated 
extrinsically by addition of distinct factors to the HSC cultures. Such conditions should induce 
cell proliferation in order to increase cell numbers with concomitant stimulation of self-renewal 
and inhibition of differentiation in order to maintain HSCs characteristics. Chapter 4 describes 
the potential of two small chemical molecules, lithium (Li, a simple cation) and valproic acid 
(VPA, a well-known histone deacetylase inhibitor) to promote maintenance of HSPC in culture 
by inhibiting cell differentiation. To assess potential anti-differentiation properties of these two 
compounds, we stimulated HSPC into differentiation with SCF and GM-CSF. We showed that 
supplementing the HSPC cytokine cultures with the combination of Li and VPA resulted in the 
preservation of an immature cell phenotype and in vitro stem cell functionality, as measured by 
CFU and CAFC assays. Moreover, anti-differentiation effects of VPA and Li were observed also 
at the level of committed progenitors, where these compounds re-activated replating activity 
of CMP and GMP cells. Strikingly, after a 7-day differentiation culture cells exposed to the 
combination of Li and VPA provided radioprotection to lethally irradiated recipients, shortened 
the time required for platelet and red blood cell recovery, and enhanced in vivo repopulation 
potential. Anti-differentiation effects of the combination of Li and VPA were confirmed at the 
molecular level. We showed that VPA and Li synergistically preserved expression of stem cell-
related genes and repressed genes involved in differentiation. Additionally, we identified genetic 
networks and putative targets that are transcriptionally affected by both compounds. This study 
provides evidence that HSC self-renewal and differentiation can be manipulated chemically by 
small molecules, representing relatively new approach in expansion studies. Additionally, our data 
suggest that combinatorial screening of chemical compounds, and other potential self-renewal 
factors may uncover possible additive/synergistic effects to modulate HSPC self-renewal and 
differentiation and thereby may lead to novel approaches in ex vivo stem cells culturing systems. 
Findings that the fate of HSPC can be modulated chemically by the addition of small 
molecules to the culture media, such as lithium and valproic acid (described in chapter 4), is 
promising in light of ex vivo HSC expansion. However, at present our understanding of the 
molecular events of chemical modulation of HSCs is limited. VPA has been used in leukemia 
treatment as a differentiation therapy. Therefore the identification of gene targets of compounds 
such as VPA is important to understand the full potential of these molecules. In Chapter 5 we 
determined the early molecular response of HSPCs to VPA treatment. Our analysis revealed 
that overrepresentation of genes involved in glutathione metabolism, receptor and signal 
transducer activity and changes in the HSPCs surface profile following short, 24h VPA treatment. 
We identified the well-known and widely used HSPC markers Sca-1 and Thy-1 as early VPA targets, 




on HSPCs. Strikingly, after 24h culture, VPA not only strongly preserved Sca-1 expression and 
the LSK phenotype of isolated HSPCs, but it also re-induced Sca-1 on committed progenitors 
(CMPs and GMPs) that had lost its expression in the process of differentiation, reverting those 
cells to a more immature LSK phenotype. Moreover, Sca-1 re-induction coincided with induced 
self-renewal capacity as measured by in vitro replating assays, while Sca-1 itself was dispensable 
for the functional effects of VPA as demonstrated using Sca-1 deficient progenitor cells. These 
data provide the first analysis of direct VPA targets in primitive hematopoietic cells and show 
that Sca-1 is a faithful marker to identify HDI-responsive cells after in vitro culture. 
FUTURE PERSPECTIVE
Expansion of HSCs has been a scientific struggle for many years and despite extensive research 
scientists have had difficulties trying to amplify or even maintain hematopoietic stem cells 
in culture. Major roadblocks have remained unanswered. What puts or keeps HSCs in a self-
renewal division mode? What are the golden standard culture conditions to support unlimited 
HSC self-renewal and proliferation? Finally, to what extent could it be possible to generate 
fully functional HSCs, and their derivatives ex vivo? Limited understanding how HSC fate 
decisions are controlled in vivo translate into limited success rate of ex vivo HSC expansion 
protocols. Therefore, to be able to effectively manipulate the hematopoietic system we first 
have to understand it. Identification of signals controlling HSC self-renewal and differentiation 
in vivo, such as intrinsic factors as well as signals from the HSC microenvironment (soluble 
growth factors, extracellular matrix and stroma components), and understanding how are they 
correlated with each other seems to be crucial for the understanding of HSC fate regulation and 
the success of HSC expansion. In this thesis we examined whether and how recently discovered 
new intrinsic molecules, microRNAs, can affect HSC self-renewal and differentiation. Such 
fundamental studies are important as they add missing pieces to the puzzle of HSC regulation 
and might eventually lead to the discovery of new molecules that could be used to expand 
HSCs  in vitro. Developments of genome-wide state-of-the-art tools to study intrinsic self-
renewal determinants, such as mRNA expression, microRNA expression, protein expression, 
post-transcriptional modifications, transcription factor binging sites and epigenetic marks, 
offer the possibility of better insights into mechanisms controlling HSC self-renewal. However, 
the limiting number of HSC per mouse makes most of these types of analysis challenging for 
the hematopoietic system that have yet to be overcome. One may think that technological 
progress and identification of new levels of gene regulation would make it easier to identify 
stem cell factors, but key determinants regulating cell stemness at present remain unknown. 
Additionally, research focused on single determinants, such as mRNA or microRNA only, do 
not fully reflect complexity of the self-renewal mechanism. Explanation and understanding 
of complex phenomena, such as self-renewal, might require an integrative approach. Likely 
not only one gene is responsible for the stem cell phenotype and more factors should be 
considered as a read-out for stem cell activity. Constructing regulatory networks (as in chapter 
4) would help to oversee which gene network or related genes are involved in co-regulation of 
important biological processes. The ultimate goal however, would be to construct regulatory 
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networks controlling HSC fate decisions that integrate multiple distinct determinants, such as 
mRNAs, non-coding RNAs or epigenetic factors, and which eventually will allow us to predict, 
model and potentially control behavior of HSCs in culture.
Difficulties in ex vivo expansion seem not to be shared by some of the other tissue-specific 
stem cell systems. Maintenance or expansion of stem cells from tissues such as embryo, epidermis, 
intestinal epithelia or retina, could be relatively easily achieved by culturing with a defined mix 
of factors that keeps the cells in a self-renewal mode and prevents successive differentiation. 
There could be several possible reasons for this difference, such as the stringency of available 
stem cell assays, growth factor dependence or stroma involvement. A hypothesized universal 
self-renewal signature was an interesting concept that could help to translate the achievement 
from other stem cell tissues to HSC. However, studies comparing mRNA expression profiles 
of HSC, embryonic and neural stem cells led to disappointing results, showing very little or no 
overlap between tested stem cell systems, suggesting that such a thing as acommon self-renewal 
signature most likely does not exists. Unfortunately, the reason for those differences in expansion 
feasibility between stem cells from distinct tissues is unknown yet. 
It has been speculated that the answer to successful HSC expansion could also be found 
by defining the cellular composition and complex molecular signals in the AGM region during 
HSC development. Several developmental factors, such as Wnt and Notch, have been shown to 
help to maintain adult HSC in culture. However, this concept is a matter of onging discussion. 
A possible alternative to improve HSC expansion protocols, not based on prior knowledge, 
is “blind” screening of hundreds of thousands of distinct factors for potential self-renewal 
enhancing effects. The first reports using high-throughput screening of chemical compound 
libraries demonstrate utility of this approach, and led to the discovery of compounds, such 
as PGE
2
 or SR1 (an aryl hydrocarbon receptor antagonist), representing new promising HSC 
expansion factors. Additionally, it has been show that full replacement of HSC cytokines could 
be beneficial for ex vivo HSC expansion by modulating strength of the signal induced by the 
cytokines. A small molecule agonist of c-Mpl receptor (receptor for a well-know and widely used 
HSC cytokine, Tpo) has been shown to improve HSC maintenance in culture compared with Tpo. 
Nowadays, thousands of molecules are screened for their effects on HSC fates and the utility 
of these factors for in vitro stem cell expansion is being investigated. The effect and stability of 
small molecules might be easier to control, and therefore it is possible that such compounds 
might replace hematopoietic factors in future expansion protocols. In this thesis we tested the 
ability of two small chemical molecules, lithium and valproic acid (chapter 4 and 5), as a new 
alternative to control HSC behavior extrinsically during culture. The ability to manipulate in vitro 
HSC properties chemically by small compounds opened a new avenue of possibilities for ex vivo 
HSC expansion protocols and also offers future possibility to design small molecules that would 
specifically and efficiently target key intrinsic HSC self-renewal factors. 
Ex vivo modeling of the BM niche is a new approach aimed to improve in vitro HSC expansion 
protocols and is based on the concept of the importance of the in vivo HSC niche for their 
maintenance. In vitro cultures of HSC can be stroma-free or stroma-dependent. Although 
stroma-free cultures are easier to standardize and maintain, it has been suggested that stroma-
dependent cultures provide a more physiological environment that could be beneficial for in vitro 




foreign human or animal antigens to the HSC expansion product. Here BM engineering offers an 
alternative solution. By the use of the naturally occurring peptides or synthetic polymers it tries 
to mimic the three-dimensional (3D) BM HSC niche. The idea of these biomaterial-based 3D-like 
matrix cultures is to provide structural support and opportunity for cell migration and adhesion 
that occurs in physiological conditions. Up till now, only a few systems for HSC culture using 
biomaterials have been proposed leaving the field of BM modeling wide-open. Also here, the 
better knowledge how exactly stem cells are regulated could facilitate the definition of key contact 
vs non-contact stem cell factors, thereby resulting in the most optimal and fully defined culture 
conditions. Furthermore, once defined and efficient HSC expansion protocols are established, 
the use of continuous perfusion culture systems or bioreactors could allow for the development 
of a therapy-suitable HSC product by providing controlled culture conditions, optimization, 
standardization and scale-up, making the end product predictable and free of contaminants.
When discussing the future perspectives of HSC expansion studies the recent discovery of 
induced pluripotent stem cells (iPSCs) needs to be mentioned. Studies by the Yamanaka lab 
showed that somatic cells could be reprogrammed and de-differentiated into stem cell-like stage 
by introduction of (in this case) four key embryonic stem cells transcription factors. Such iPSC cells 
could be then further differentiated into HSC. Alternatively differentiated hematopoietic cells or 
any other somatic cells that could be easily harvested from the patient's might be possibly directly 
reprogrammed into HSC. This discovery can potentially revolutionize the field of HSC expansion 
and offers the possibility of production of unlimited numbers of stem cells from patients own 
somatic cells. However, there are many questions to be addressed before cellular reprogramming 
could become a real alternative to traditional HSC expansion approaches.
The biological properties and clinical potential of HSCs elicit continued scientific, 
commercial and public interest. Our ability to expand HSC ex vivo could benefit stem cell 
transplantation and gene therapy protocols. In recent years, combined efforts of the scientific 
and industrial community to improve HSC expansion have been promising. Most of the recent 
developments, such as screening of molecule libraries, developing 3D scaffolds mimicking 
the BM niche, or use of bioreactors, are the result of such collaborations. Scientifically-driven 
approaches for new discoveries combined with systematic industrial-based knowledge and 
experience might in the future offer viable HSC expansion protocols. Although HSCs are the 
best studied stem cell system, at present the secret of their self-renewal remains hidden, and 
so does our ability to manipulate HSC in vitro. With many remaining questions it is realistic to 
say that we are just beginning to understand how HSCs properties are regulated and how to 
use this knowledge to manipulate culture conditions of HSC for clinical purposes. Additionally, 
development of reliable and good in vivo models for human stem cell read-out would help 
to better validate existing and future stem cell protocols. Based on HSC behavior and their 
expansion potential in vivo, we believe that unlimited in vitro HSC amplification is feasible. 
However with only small steps behind us, achieving this “holy grail” of expansion research 
might require additional years of research. What the future of ex vivo HSC expansion will bring 
is an intriguing question. What would be the winning combination of HSC expansion factors for 
clinical ex vivo HSC protocols? Based on present knowledge it is feasible to say that it would be 
a combination of several factors, such as cytokines and small molecules, and just the right ratio 
to induce the perfect balance between proliferation and self-renewal.











NEDERLANDSE SAMENVATTING (VOOR NIET-INGEWIJDEN)
Hematopoiese is het proces van bloedcelontwikkeling en de uiteindelijke productie van rijpe 
bloedcellen. Bloed bestaat uit vele verschillende, gespecialiseerde cellen die een belangrijke 
rol spelen in een organisme. Ze vervullen uiteenlopende functies zoals vervoer van zuurstof 
naar alle weefsels in het lichaam (rode bloedcellen), verdediging tegen pathogenen (witte 
bloedcellen) en bloedstolling (bloedplaatjes). Veel van deze gespecialiseerde, rijpe cellen 
hebben een zeer korte levensduur en ze moeten dus voortdurend worden vervangen. 
Ongeveer 1011–1012 nieuwe bloedcellen worden hiervoor dagelijks geproduceerd. Deze 
productie van nieuwe cellen is afhankelijk van een kleine populatie van bloedvormende cellen, 
namelijk hematopoïetische stamcellen (HSC). HSC kunnen zich differentiëren in elk type van 
volwassen bloedcellen, maar ze kunnen ook hun eigen populatie in stand houden in een proces 
dat zelfvernieuwing (self-renewal) wordt genoemd. De balans tussen deze twee processen is 
cruciaal voor een organisme want het maakt een snelle en robuuste reactie op fysiologische 
stress, zoals bloedverlies, infectie en verwonding (multilineaïre differentiatie) mogelijk en 
bloed productie is zo gegarandeerd voor een leven lang (zelfvernieuwing).
De eigenschappen van HSCs maken deze cellen een aantrekkelijke bron voor een 
breed scala van op stamcellen gebaseerde therapieën waar herstel van bloedcellen of van 
normale hematopoïese nodig is. Dit is onder andere het geval bij de behandeling van kanker, 
beenmergfalen, immuundeficiënties en genetische aandoeningen, waarbij HSC transplantatie 
een levensreddende procedure kan zijn. Echter, ieder mens is anders en om een transplantatie 
succesvol te maken, moeten de HSC van donor en de patiënt immunologisch worden afgestemd. 
Een goede match voorkomt afstoting van de getransplanteerde cellen en immuunreacties van 
deze cellen die gericht zijn tegen de ontvanger. De beperkte beschikbaarheid van geschikte 
HSC uit beenmerg en gemobiliseerde perifere bloed beperkt het gebruik ervan. Het gebruik 
van navelstrengbloed (UCB) als bron van stamcellen is eerder geschikt, doordat een kleine 
mismatch mogelijk is.  Het aantal stamcellen in een UCB is echter niet voldoende voor 
transplantatie in een volwassene, wat ook het gebruik van UCB beperkt. Daarom wordt veel 
onderzoek gedaan naar vermeerdering van HSC aantallen (expansie) ex vivo, voorafgaand aan 
de transplantatie. Tegenwoordig kunnen we slechts één patiënt behandelen met de HSC uit 
een UCB en de uitdaging is om ongedifferentieerde HSC te vermeerderen (via stimulatie van 
zelfvernieuwing) zodat de aantallen voldoende zijn voor de behandeling van volwassen patiënten 
of zelfs meerdere patiënten. Het succes van ex vivo stamcel expansie protocollen is afhankelijk 
van ons vermogen om het gedrag van HSC te manipuleren; om de celdeling te stimuleren en 
het gelijktijdig behouden van de cel in een ongedifferentieerde staat. De ontwikkeling van 
dergelijke protocollen vereist het begrijpen van de mechanismen die HSC zelfvernieuwing 
en differentiatie beïnvloeden, en uiteindelijk het definiëren van de belangrijkste factoren die 
HSC zelfvernieuwingsceldelingen stimuleren. In dit proefschrift hebben we de mogelijkheden 
van verschillende factoren om HSC zelfvernieuwing en differentiatie te reguleren onderzocht 
met het uiteindelijke doel mogelijkheden voor ex vivo stamcellen expansie te verkennen. 
Tijdens de celdeling moet de HSC kiezen tussen zelfvernieuwing en differentiatie, en de 
balans tussen deze twee keuzes bepaalt de uitkomst van ex vivo expansie cultuur. Het lot van 
HSC wordt gereguleerd door signalen zowel van binnenin de cel (intrinsiek) als signalen van 
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buitenaf (extrinsiek). In hoofdstuk 3 hebben we geprobeerd om nieuwe intrinsieke regulatoren 
van hematopoïese te identificeren. Het lot van de cel is geprogrammeerd in het DNA, een 
genetische code van de cel die wordt vertaald naar RNA niveau en verder naar eiwitniveau. 
De genetische code van de cel kan worden beïnvloed door andere intrinsieke moleculen, 
zoals niet-coderende RNA’s, waaronder microRNA’s. MicroRNA’s zijn korte RNA moleculen die 
kunnen binden aan RNA en het RNA waaraan zij binden inactiveren zodat dit partner RNA niet 
functioneel meer is. In hoofdstuk 3 hebben we onderzocht of microRNA’s de zelf-vernieuwing 
van HSC kunnen beïnvloeden en het aantal HSC kunnen vermeerderen. Om dit te onderzoeken, 
hebben we microRNA expressiepatronen onderzocht tijdens differentiatie in vier verschillende 
hematopoïetische celtypes (stamcellen, voorlopercellen, en rijpe myeloïde en erythroïde 
cellen) en uit twee verschillende muizenstammen die verschillen in aantallen HSC’s. We hebben 
ons gericht op die microRNA’s die ten eerste actief waren in stamcellen en/of voorlopercellen 
en minder of nauwelijks actief in rijpe bloedcellen, en ten tweede de microRNA’s die het meest 
actief waren in de muizenstam met de meeste bloedvormende stamcellen. Deze criteria zouden 
microRNA’s kunnen identificeren die betrokken zijn bij de regulatie van stamcellen. Dit leidde tot 
de identificatie van een evolutionair geconserveerd microRNA cluster bestaande uit miR-99b, 
let-7e en miR-125a. De functie van dit microRNA cluster werd onderzocht door overexpressie 
van het hele cluster en individuele leden van het cluster in de beenmergcellen. Hiermee hebben 
we het effect van de overexpressie in verschillende stamcellen en voorlopercellen getest in 
vitro en in vivo assays. We vonden dat cellen na overexpressie van het microRNA 99b/let7e/125a 
cluster aanvankelijk in een stamcelachtige staat bleven. Maar normale bloedvorming werd 
verstoord in de muizen die getransplanteerd waren met de miR-cluster cellen. Gedetailleerde 
analyse van het stamcel compartiment van deze muizen liet zien dat HSC na overexpressie 
van het miR-cluster 99b/let-7e/125a sterk waren aangetast, waardoor dit na verloop van tijd 
resulteerde in uitputting van stamcellen. Het miR-125a  werd geïdentificeerd als het microRNA 
in dit cluster dat verantwoordelijk is voor het merendeel van de miR-cluster 99b/let-7e/125a 
overexpressie fenotypes. Ook zijn in deze studie een aantal kandidaat-partner RNA-moleculen 
van de geteste microRNAs gevonden. De microRNA 125a kan binden aan deze partners en hun 
translatie tot eiwit-niveau blokkeren, wat mogelijk het lot van de stamcellen kan beïnvloeden.
Omdat het inbrengen van genetisch materiaal in cellen kan leiden tot ongewenste klinische 
resultaten na transplantatie (bijvoorbeeld de ontwikkeling van leukemie), zal stimulering 
van HSC amplificatie door extrinsieke factoren het geprefereerde middel zijn om klinische 
ex vivo stamcellen te expanderen. Echter, tot nu toe is er beperkt succes bij het voorkomen 
van HSC differentiatie met extrinsieke factoren en zonder genetische manipulatie. Eén 
van de belangrijkste problemen van ex vivo expansie protocollen is het onvermogen om 
stamceldifferentiatie te voorkomen en gelijktijdig celproliferatie te stimuleren. Recent is 
aangetoond dat kleine chemische moleculen kunnen worden gebruikt als nieuwe instrumenten 
voor het manipuleren van het lot van de stamcel. Hoofdstuk 4 beschrijft de mogelijkheden van 
twee van deze kleine chemische moleculen, namelijk lithium (Li, een eenvoudige kation) en 
valproïnezuur (VPA, een bekende histon-deacetylase-remmer). Er is onderzocht wat hun effect 
is op het remmen van stamceldifferentiatie en dus het behoud van HSC in kweek. De toevoeging 




leidde tot sterke anti-differentiatie effecten. Dit werd aangetoond in verschillende in vitro en in 
vivo assays voor stamcellen en voorlopercellen. De combinatie van VPA en Li behield de onrijpe 
morfologie van de cellen en verbeterde de stamcel uitlezing na transplantatie. Bovendien 
zouden VPA en Li niet alleen differentiatie remmen van stamcellen, maar ook zelf-vernieuwing 
induceren van voorlopercellen. Verder hebben we aangetoond dat VPA en Li synergistisch 
de genetische code die specifiek is voor stamcellen en voorlopercellen kunnen behouden. 
Ook hebben we moleculen geïdentificeerd waarop VPA en Li hun anti-differentiatie effecten 
waarschijnlijk uitoefenen. Deze zogenoemde targets waren sterk gecorreleerd met elkaar 
tijdens normale stamceldifferentiatie, wat suggereert dat zelfvernieuwing en differentiatie 
van elkaar afhankelijke processen zijn. Deze beide processen dienen derhalve beïnvloed te 
worden in kweken om ex vivo stamcellen te expanderen. Dit maakt het mogelijk dat additieve/
synergistische effecten van chemische verbindingen en andere mogelijke factoren die 
zelfvernieuwing beïnvloeden in een combinatorische screening ontdekt kunnen worden. Dit 
zou kunnen leiden tot nieuwe benaderingen om zelfvernieuwing en differentiatie van HSC te 
moduleren in ex vivo kweken voor stamcelexpansie. Bevindingen dat het lot van HSC kan worden 
gemoduleerd door de toevoeging van kleine chemische moleculen aan het kweekmedium is 
gunstig in het licht van ex vivo HSC expansie. Dit biedt, naast cytokines en ontwikkelingsfactoren 
aanvullende manieren voor controle over HSC zelfvernieuwing en differentiatie in vitro. Op dit 
moment, echter, is ons begrip van de moleculaire gebeurtenissen door chemische modulatie 
van HSC beperkt. Bovendien wordt VPA gebruikt in leukemie behandelingen als differentiatie 
therapie en derhalve is de specifieke identificatie van de effecten op stamcellen van belang om 
het potentieel van verbindingen zoals VPA begrijpen. In hoofdstuk 5 hebben we de genetische 
respons van de HSC op korte termijn VPA behandeling gekarakteriseerd, omdat de analyse van 
genen die door VPA worden beïnvloed (doelwitgenen) kan helpen om het volledige spectrum 
van de effecten ervan beter te begrijpen. Onze analyses toonden aan dat een korte, 24-uurs 
VPA behandeling verschillende cellulaire processen beïnvloed. Hieronder bevinden zich onder 
andere de activiteit van receptoren en hun signaal transductie, en veranderingen in HSC 
oppervlaktemarkers. Stamcellen kunnen worden geïdentificeerd door de aanwezigheid van 
de afwezigheid van specifieke markers op hun oppervlak. Bekende en veel gebruikte markers 
voor HSC, namelijk Sca-1 en Thy-1 werden geïdentificeerd al VPA doelwitgenen. Bijzonder is 
dat vooral Sca-1 in vele identificatiestrategieën voor muizen-HSC gebruikt wordt om het 
stamcelcompartiment van het meer gedifferentieerde myeloïde compartiment te scheiden. 
Stimulatie van hematopoïetische cellen met VPA zorgde voor behoud van Sca-1 expressie op de 
HSC’s, maar ook werd Sca-1 opnieuw geïnduceerd op myeloïde progenitorcellen, die de expressie 
hadden verloren tijdens het proces van differentiatie. Hierdoor kregen de voorlopercellen 
weer het fenotype van een onrijpe stamcel. Stamcellen worden niet alleen gedefinieerd door 
de aanwezigheid van de specifieke markers maar vooral door hun functionele mogelijkheden. 
Belangrijk is dat de functionaliteit toegenomen was van stamcellen die de Sca-1 marker opnieuw 
verworven hadden en de mate van functionaliteit correleerde met de expressie van Sca-1. 
Maar re-inductie van functionele mogelijkheden was niet afhankelijk van het Sca-1 molecuul 
zelf, wat suggereert dat Sca-1 is een marker van cellen die stamcelachtige eigenschappen 
herwinnen. We kunnen dus zeggen dat VPA belangrijke effecten heeft op hematopoïetische 
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stamcellen en hun zelfvernieuwing en differentiatie kan induceren en mogelijk ex vivo kweken 
voor stamcelexpansie zou kunnen verbeteren. Hoewel HSC één van de best bestudeerde 
stamcel-systemen is, zijn op dit moment de geheimen van hun zelf-vernieuwing nog steeds 
niet bekend. En zo blijft ons vermogen om effectief HSC in vitro te manipuleren beperkt. Het 
bepalen hoe verschillende cel-intrinsieke en extrinsieke cel-signalen met elkaar geïntegreerd 
zijn en de identificatie van regulerende netwerken die HSC zelfvernieuwing controleren, lijkt 
cruciaal om succesvolle expansie protocollen te ontwerpen. Wat de toekomst van de ex vivo 
HSC expansie zal brengen is een intrigerende vraag. Wat zou de winnende combinatie van HSC 
expansie factoren zijn, die geschikt blijken voor klinische HSC protocollen? Op basis van de 
huidige kennis is het mogelijk om te zeggen dat het een combinatie van verschillende factoren 
zal zijn, zoals cytokines en kleine moleculen, waarvan precies de juiste verhouding nodig is 





Hematopoiesis is the process of blood cell development and formation. Blood consists of many 
distinct and specialized cells that play an important role in an organism function, from oxygen 
supply (red blood cells) to all tissues in the body, protection and defence against pathogens 
(white blood cells) to blood coagulation (platelets) in case of injury. Many of these specialized, 
mature cells have a very short life span and they need to be continuously replaced. 
Approximately 1011–1012 new blood cells are produced daily. This rapid cell turnover is dependent 
on a small population of blood-forming cells, namely hematopoietic stem cells (HSCs). HSCs 
can differentiate into any type of mature blood cell types, but they can also re-produce 
themselves in a process of self-renewal to maintain the stem cell pool. The balance between 
these two processes is crucial for an organism as it enables rapid and robust response to 
physiological stresses, including blood loss, infection and injury (multilineage differentiation) 
and it maintains lifelong blood production (self-renewal). The properties of HSCs render these 
cells an attractive source for a wide range of stem cell-based therapies where restoration of 
blood cells or introduction of normal hematopoiesis is needed. This can be the case in the 
treatment of cancer, bone marrow failure, immunodeficiencies and genetic disorders, where 
HSC transplantation can be a life-saving procedure. However, each human is different and in 
order for a transplantation to be successful the HSC from donor and patient have to be matched 
immunologically. This will prevent rejection of the transplanted cells and immune reactions 
from the graft against the recipient. The low availability of suitable, matched HSC from bone 
marrow and mobilized peripheral blood restricts their use. An alternative approach, allowing 
the use of more rapidly available mismatched donors, involves the use of umbilical cord blood 
(UCB). However, the stem cell number in a single UCB unit is not sufficient for transplantation 
into an adult, limiting the use of UCB. Therefore much research focuses on amplification of HSC 
numbers ex vivo (outside the organism), prior their transplantations. Nowadays we can treat 
only one patient with the HSCs from a single UCB unit and the challenge is to expand 
undifferentiated HSCs (via stimulation of self-renewal) in numbers sufficient for therapy of 
adult patients or even several patients. The success of ex vivo stem cell expansion protocols is 
dependent on our ability to manipulate the behavior of HSCs; to stimulate cell division with 
concomitant maintenance of an undifferentiated cell state. The development of such protocols 
requires the understanding of the mechanisms governing HSCs self-renewal and differentiation 
decisions, and ultimately defining key factors stimulating HSCs self-renewal divisions. In this 
thesis we aimed to explore the potential of distinct factors to regulate HSCs self-renewal and 
differentiation with the ultimate purpose of ex vivo stem cell expansion. During cell division the 
HSC has to choose between self-renewal and differentiation, and the balance between these 
two cell fates determines the outcome of ex vivo expansion culture. The fate of HSC is regulated 
by signals from both inside (intrinsic) and outside (extrinsic) of the cell. In chapter 3 we aimed 
to identify new intrinsic regulators of hematopoiesis. Cellular fate is programmed in the DNA, a 
genetic code of the cell that is translated to RNA levels and further to protein level. Genetic 
code of the cell can be influenced by other intrinsic molecules, such as non-coding RNAs, 
including microRNAs. MicroRNAs are short RNA molecules that can bind to RNA and inactivate 
the partner RNA so that RNA is not functional. In chapter 3 we investigated whether microRNAs 
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can influence the self-renewal of HSCs and thereby increase their numbers. To determine this 
we profiled microRNA expression patterns during hematopoietic differentiation in four distinct 
types of cells (stem cells, progenitor cells, and mature myeloid and erythroid cells) from two 
different strains of mice that differ in the frequency of HSCs. We focused on those microRNAs 
which first were active in stem cells and/or progenitor cells and less or hardly active in mature 
blood cells, and second that were most active in the mouse strain with the most blood-forming 
stem cells. These criteria could identify microRNAs that might be involved in stem cell fate 
regulation. This led to identification of an evolutionary conserved microRNA cluster consisting 
of miR-99b, let-7e and miR-125a. The function of this microRNA cluster was investigated by 
overexpressing the entire cluster and individual members of the cluster in the bone marrow 
cells. Subsequently, we tested the effect of overexpression in several stem and progenitor cell 
in vitro and in vivo assays (outside the organism or inside the organism, respectively). We found 
that cells overexpressing microRNA 99b/let7e/125a cluster were initially preserved in a stem 
cell-like state. Additionally, blood formation was disturbed in the mice transplanted with the 
miR-cluster cells. Detailed analysis of stem cell compartment from these mice revealed that 
HSCs overexpressing miR-cluster 99b/let-7e/125a were significantly compromised, resulting 
over time in stem cell exhaustion. The single microRNA, miR-125a was identified to be 
responsible for the majority of the miR-cluster 99b/let-7e/125a overexpression phenotypes. 
Also in this study a number of candidate partner RNA molecules of tested microRNAs were 
found. The microRNA 125a could bind to them and block their conversion to protein level, 
possibly influencing the stem cells fates. Since introduction of genetic material can result in 
undesired clinical outcomes following transplantation (e.g development of leukemia), 
stimulation of HSC amplification by extrinsic factors is the preferred tool for clinical ex vivo 
stem cell expansion. However, so far there has been limited success in preventing HSC 
commitment and differentiation with extrinsic factors and without genetic manipulation. 
One of the main problems of ex vivo expansion protocols is the inability to prevent stem cell 
differentiation with concomitant stimulation of cell proliferation. Recently it has been shown 
that small molecules could be used as new tools for manipulating cell fate decisions. Chapter 
4 describes the potential of two small chemical molecules, lithium (Li, a simple cation) and 
valproic acid (VPA, a well-known histone deacetylase inhibitor) to promote maintenance of 
HSC in culture by inhibiting stem cell differentiation. The addition of the combination of these 
two compounds, Li and VPA, to differentiation-stimulating cultures of HSC resulted in strong 
anti-differentiation effects as shown by distinct stem and progenitor cell in vitro and in vivo 
assays. The combination of Li and VPA preserved immature morphology of the cells and 
improved the stem cell read-out following transplantation. Moreover, VPA and Li could not 
only inhibit differentiation of stem cells, but also induced self-renewal of progenitor cells. 
Further, we documented that VPA and Li synergistically preserved genetic code specific for stem 
and progenitor cell and we identified molecular targets of VPA and Li by which they could exert 
their anti-differentiation effects. Identified VPA and Li targets were strongly correlated with 
each other during normal hematopoietic differentiation, suggesting that self-renewal and 
differentiation seem to be strongly co-dependent. Thus, ex vivo stem cell culturing systems should 




chemical compounds, and other potential self-renewal factors may uncover possible additive/
synergistic effects to modulate HSC self-renewal and differentiation. This may ultimately lead 
to novel approaches in ex vivo stem cells culturing systems. Findings that HSCs fate can be 
modulated chemically by the addition of small molecules to the culture media is convenient in 
the light of ex vivo HSC expansion. This offers, next to cytokines and developmental factors, an 
additional level of control of HSC self-renewal and differentiation decisions in vitro. However, 
at present our understanding of the molecular events of chemical modulation of HSC is limited. 
Moreover, VPA has been used in leukemia treatment as a differentiation therapy and therefore 
detailed identification of its stem cell effects is of importance to understand the full potential of 
compounds such as VPA. In chapter 5 we characterized the genetic response of the HSC to 
short-term VPA treatment, since the analysis of VPA target genes may help to better understand 
the full spectrum of its effects. Our analyses revealed that short, 24h VPA treatment affected, 
among others, the activity of the receptor and the signal transducer activity and changes in the 
HSPCs surface marker profile. Stem cells can be identified by the presence or the absence of 
specific markers on their surface. Well-known and widely used HSPCs markers, namely Sca-1 
and Thy-1 were identified as early VPA targets. Particularly, Sca-1 is included in many murine 
HSC identification strategies, separating the stem cell compartment from a more differentiated 
myeloid compartment. Stimulation of hematopoietic cells with VPA preserved Sca-1 expression 
on the HSCs, but it also re-induced Sca-1 marker on myeloid progenitor cells that had lost its 
expression in the process of differentiation, reverting those cells to a more immature stem cell 
phenotype. Stem cells are defined not only by the presence of the specific markers, but most 
importantly by their functional potential. Strikingly, the functionality of progenitor cells that 
re-acquired Sca-1 marker was also increased correlating with reversion of Sca-1. However, re-
induction of cell functional potential was not dependent on Sca-1 marker, suggesting that Sca-1 
is a marker of cells with stem cell-like phenotype. Collectively, we can say that VPA can induce 
important effects on hematopoietic stem and progenitor cell self-renewal and differentiation 
and could improve ex vivo stem cell expansion cultures. Although HSCs are the best studied 
stem cell system, at present the secret of their self-renewal remains hidden, and so does our 
ability to effectively manipulate HSCs in vitro. Defining how various cell-intrinsic and cell-
extrinsic signals are integrated with each other and the identification of regulatory networks 
controlling HSCs self-renewal seems to be crucial to be able to design successful expansion 
protocols. What the future of ex vivo HSCs expansion will bring is an intriguing question. What 
would be the winning combination of HSCs expansion factors for ex vivo clinical HSC protocols? 
Based on present knowledge it is feasible to say that it would be a combination of several 
factors, such as cytokines and small molecules and just the right ratio to induce the perfect 
balance between proliferation and self-renewal. 
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SUMMARy IN POLISH 
PODSUMOWANIE (DLA GENERALNEJ PUBLICZNOśCI)
Proces wytwarzania i różnicowania się krwi zwany jest hematopoezą. Krew składa się z wielu 
różnych rodzajów komórek, które odgrywają ważną rolę dla prawidłowego funkcjonowania 
organizmu. Na przykład, czerwone krwinki (erytrocyty) dostarczają tlen to wszystkich 
pozostałych komórek w organizmie, białe krwinki (leukocyty) chronią przed i zwalczają zakażenia, 
a płytki krwi odpowiedzialne są za krzepnięcie krwi po zranieniu. Wiele z tych zróżnicowanych 
i wyspecjalizowanych komórek ma ograniczony czas życia i muszą być one ciągle odtwarzane. 
Codziennie we krwi produkowane jest około 1011-1012 nowych komórek. Za produkcję nowych 
komórek, a także za ciągłość procesu tworzenia krwi odpowiedzialne są komórki macierzyste 
krwi. Komórki te posiadają bardzo szczególne właściwości, mianowicie mogę one zróżnicować 
się w każdy rodzaj komórek obecnych we krwi, ale mogą one również odtworzyć same 
siebie. Zdolność komórek macierzystych krwi do reprodukcji swoich identycznych kopii 
gwarantuje, że krew jest tworzona przez cały okres życia organizmu. Wspomniane dwie cechy 
charakterystyczne komórek macierzystych krwi, zdolność tworzenia wszystkich rodzajów 
komórek krwi i reprodukcji samych siebie, jest wykorzystywana w praktyce przy leczeniu chorób 
gdzie wymagane jest  odtworzenie produkcji krwi, jak np, w leczeniu raka, niewydolności 
szpiku kostnego czy też w chorobach genetycznych. Pomimo ogromnego potencjału komórek 
macierzystych krwi, ich kliniczne zastosowanie jest ograniczone. Tradycyjnymi źródłami 
komórek macierzystych krwi są szpik kostny i krew. Jakkolwiek, aby leczenie (transplantacje) 
komórkami macierzystymi się powiodło, komórki pacjenta i dawcy muszą być identyczne lub 
bardzo podobne pod względem immunologicznym. Jednak każdy organizm, każdy pacjent 
jest inny i znalezienie odpowiedniego dawcy (bliźniaka genetycznego) jest bardzo trudne, a 
w  wielu przypadkach niemożliwe. Alternatywnym źródłem komórek macierzystych krwi jest 
krew pępowinowa, która nie musi być dokładnie dopasowana genetycznie, aby leczenie się 
powiodło. Jednak i tutaj istnieją obecnie pewne ograniczenia. Ilość komórek macierzystych 
krwi w jednostce krwi pępowinowej jest niewystarczająca do terapii dorosłego pacjenta. 
Dodatkowo, ilość komórek macierzystych różni się znacznie pomiędzy dawcami. Namnożenie 
komórek macierzystych przed podaniem ich pacjentowi może znacznie poprawić użyteczność 
krwi pępowinowej, a także może umożliwić leczenie dorosłych pacjentów lub nawet kilku 
pacjentów komórkami pochodzącymi z jednej jednostki krwi pępowinowej. Obecnie wiele 
badań jest prowadzonych mających na celu namnożenie komórek macierzystych krwi in 
vitro, czyli poza organizmem, w naczyniu laboratoryjnym. Moja praca doktorska zajmuje się 
właśnie tym problemem. W rozdziałach tej książki opisane są badania skupiające się na lepszym 
scharakteryzowaniu i poznaniu w jaki sposób komórki macierzyste odtwarzają same siebie. 
Dodatkowo, nowe metody hodowli komórek macierzystych zostały zaproponowane. W celu 
zwiększenia liczby komórek, komórka musi się podzielić na dwie komórki, te dwie nowe komórki 
na cztery, itd. Sukcesem do namnożenia komórek macierzystych in vitro jest zdolność stymulacji 
podziałów gdzie początkowa komórka macierzysta będzie odtwarzała samą siebie wiele razy. 
Jeśli komórka się zróżnicuje, traci ona zdolność rekonstrukcji krwi podczas transplantacji. Jak 
dotąd nie zidentyfikowano optymalnych warunków stymulujących samoodnowę komórek 
macierzystych. Decyzje o losie komórki podczas jej podziału (samoodnowa lub różnicowanie) 
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są regulowane przez informacje genetyczną komórki i czynniki wewnątrz komórki, ale także 
czynniki z otoczenia komórki mogą mieć wpływ na jej los. W rozdziale 3 tej książki opisane są 
nowo odkryte „wewnętrzne” czynniki regulujące los komórki, tak zwane microRNA. W rozdziale 
tym zidentyfikowane zostały microRNA charakterystyczne dla komórek macierzystych 
krwi. Efekt wybranych microRNA (microRNA-99b/let7e/125a) na decyzje samoodnowy lub 
różnicowania komórek macierzystych krwi został tutaj zbadany. Zidentyfikowane microRNA 
początkowo zwiększyły wydajność transplantacji, jednak szczegółowe badania pokazały, że 
balans pomiędzy samoodnową a różnicowaniem był zaburzony, na korzyść różnicowania. 
Dodatkowo, mechanizm działa microRNA-99b/let7e/125a został zaproponowany. W rozdziale 
4 zastosowana zostało inna strategia. Poprzez zewnętrzną stymulacje komórek próbowano 
zahamować różnicowanie komórek macierzystych w hodowli. Niedawno odkryta zdolność 
regulowania losu komórek macierzystych poprzez małe cząsteczki została tutaj wykorzystana. 
W rozdziale 4 pokazano, że lit i kwas waproinowy, w połączeniu, mogą zahamować lub też 
opóźnić różnicowanie komórek macierzystych krwi w hodowli. Anty-różnicujące efekty litu i 
kwasu waproinowego zostały pokazane in vitro jak i in vivo. Synegistyczny mechanizm działa 
litu i kwasu waproinowego został zidentyfikowany w szeregu testów. Genetyczne podłoże 
efektu hamującego różnicowanie zostało także tutaj zaproponowane. W rozdziale 5 mechanizm 
działania kwasu waproinowego na komórki macierzyste krwi został zbadany i opisany bardziej 
szczegółowo. Do tej pory do hodowli komórek macierzystych używano klasycznych czynników 
wzrostowych dla tych komórek. Opisana tutaj praca pokazuje, że małe cząsteczki także mogą 
regulować zachowanie komórek macierzystych krwi w hodowli, i sugeruje, że testowanie 
kombinacji rożnych czynników może doprowadzić do rozwoju nowych, lepszych systemów do 
hodowli komórek macierzystych krwi. 
Wiele lat badań wciąż przed nami, aby poznać tajemnice mechanizmu samoodnowy 
komórek macierzystych i odkrycie optymalnych warunków do ich hodowli. Na podstawie tego 
co wiemy do tej pory, można przypuszczać, że będzie to kombinacja wielu różnych czynników 
i cząsteczek, a także odpowiedniego balansu pomiędzy nimi. Interesującym i ekscytującym 
pytaniem jest jak przyszłe systemy hodowli komórek macierzystych będą wyglądały i jakie 
czynniki hodowli będą zwycięzcami wyścigu o nielimitowane namnożenie nieróżnicowanych 
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